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The CRISPR/Cas9 system is an exceedingly powerful technology for precise genome editing. 
Its ease of use, high editing efficiency and an ever-growing CRISPR-based toolbox has 
provided researchers with novel possibilities to unravel the molecular and systemic 
consequences of changes in the genetic code. For this reason, CRISPR is now applied for 
editing in a wide range of different cell lines and organisms for basic and translational research. 
Here, accurate and precise editing is an indispensable prerequisite to generate reliable 
research models. However, a lot remains to be understood about the molecular mechanism of 
double-strand-breaks (DSBs) in the DNA as introduced by the Cas9 nuclease during editing. 
In fact, CRISPR editing can be accompanied by inadvertent genomic changes at the targeted 
locus (on-target) as well as other genomic sites (off-target). These can have drastic 
consequences on gene activity or expression and therefore need to be carefully investigated.  
Characterizing and avoiding unwanted off-target effects (OffTE) has been the focus of several 
studies and reliable tools for their detection have been developed. This is, however, not the 
case for on-target effects (OnTE) that have only been reported very recently. These can be 
large deletions, large insertions, complex rearrangements, or regions of copy-neutral loss of 
heterozygosity (LOH) around the target site. Several studies have described frequent 
occurrence of OnTEs in mice, but it has not been investigated if clinically relevant human cells, 
such as induced pluripotent stem cells (iPSCs) are also affected. The main problem with 
OnTEs is that they often remain unnoticed in standard quality controls like Sanger genotyping 
of the target locus, and additional checks are lacking in most CRISPR-based studies. This is 
also because there are no simple detection tools available.  
Therefore, in this study, we developed simple and reliable tools for OnTE detection after 
CRISPR genome editing: Structural alterations like large deletions, large insertions or complex 
rearrangements can be identified by quantifying the number of intact alleles at the edited locus 
using our new method called quantitative genotyping PCR (qgPCR). In addition, we validated 
genotyping of neighboring single nucleotide polymorphisms (SNPs) either by Sanger 
sequencing or SNP microarrays to reveal editing-induced regions of LOH. The entire workflow 
is broadly applicable to different cell lines and organisms after editing by the NHEJ or HDR 
pathway.  
We have applied our newly established detection technology to human iPSCs after HDR-
mediated editing and demonstrate universal occurrence of OnTEs at multiple loci in up to 40% 
of edited single-cell clones. Furthermore, using an in vitro model of Alzheimer’s disease, we 
illustrate deleterious consequences of OnTEs on expression of the edited gene that may 




Overall, the threat of undetected OnTEs undermining the reliability of CRISPR-based studies 
has not received sufficient attention in the field so far. With this thesis, we hope to raise further 
awareness and propose that our simple and reliable on-target quality control workflow should 
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1.1 The CRISPR/Cas9 system revolutionizes biomedical research 
The idea of modifying the genomic sequence of living cells or organisms at will is a fascinating 
thought that has become reality with the recent discovery of the CRISPR/Cas9 system. It 
enables precise insertion or exchange of specific DNA sequences at virtually any genomic 
locus in a simple and rapid way. This drastically transforms the approach of many molecular 
biologists to unravel the connection between the genomic sequence and specific phenotypes, 
thereby opening endless new possibilities for basic research (reviewed in Hsu et al., 2014; 
Knott & Doudna, 2018; Komor et al., 2017; Wright et al., 2016). Furthermore, with several 
CRISPR-based clinical trials being currently conducted, its application for the treatment of 
genetically-encoded human diseases is in the immediate future (reviewed in Ernst et al., 2020; 
Mullard, 2020).  
 
1.1.1 A bacterial immune system is transformed into a genome editing tool 
The CRISPR/Cas9 system was initially discovered to be part of the adaptive immune system 
of bacteria and archaea as defense mechanism against foreign nucleic acids of invading 
bacteriophages (Barrangou et al., 2007; Brouns et al., 2008). During an invasion, foreign DNA 
is cleaved and incorporated as spacer sequences into the clustered regularly interspaced short 
palindromic repeats (CRISPR) array that contains multiple spacers from previous attacks. 
These spacers are then continuously expressed as CRISPR-RNA (crRNA) that bind to a trans-
activating crRNA (tracrRNA) as well as the CRISPR-associated (Cas9) nuclease. This 
complex can then recognize a repeated attack by the same virus through the spacer sequence, 
which leads to targeted cuts in the bacteriophage DNA and its subsequent degradation 
(Deltcheva et al., 2011; Jinek et al., 2012) (Figure 1). Realizing the potential of this RNA-guided 
nuclease system for genome editing, it was shown that purified Cas9 can be programmed to 
cut and thereby introduce targeted changes into DNA in vitro (Gasiunas et al., 2012; Jinek et 
al., 2012) as well as in vivo into the genomic DNA of cultured human cancer cell lines and 
induced pluripotent stem cell lines (Cho et al., 2013; Cong et al., 2013; Jinek et al., 2013; Mali 
et al., 2013).  
Starting with these first studies reporting successful genome editing using the CRISPR/Cas9 
system, many researchers were fascinated by its ease of use and wide applicability. In the 
next years, a lot of effort was made to characterize the underlying molecular mechanism and 




Figure 1: Mechanism of CRISPR-based adaptive immunity. Adaptation (top): Foreign nucleic acids 
from invading bacteriophages are processed and inserted as new spacer sequence into the CRISPR 
array. The CRISPR array contains spacer sequences from previous attacks segregated by repeat (R) 
elements. crRNA biogenesis (middle): The CRISPR array is transcribed and processed into individual 
crRNAs that assemble (e.g., with Cas9 and a tracrRNA) into an effector complex. Interference (bottom): 
The effector complex recognizes a repeated attack by the bacteriophage and initiates degradation of 
the foreign DNA. Image modified from Wright et al., 2016. 
 
1.1.2 Introducing targeted DNA DSBs using the CRISPR/Cas9 system 
The power of the CRISPR/Cas9 system is that targeted DSBs can be introduced into the DNA 
at a desired locus. This requires a complex of only two components: a single guide RNA 
(sgRNA) (which is an artificial fusion of crRNA and tracrRNA (Jinek et al., 2012)) and the Cas9 
endonuclease. The sgRNA contains a scaffold sequence for interaction with the Cas9 
nuclease and a 20 nucleotide (nt) spacer sequence at its 5’ end that is complementary to the 
target locus. This spacer sequence guides the Cas9 nuclease to its DNA target (protospacer) 
by complementary base-pairing and thereby determines the specificity of the complex. To 
utilize this system for genome editing, the spacer sequence of the sgRNA can be exchanged 
freely. The only requirement is the presence of a 5’-NGG’ protospacer adjacent motif (PAM) 
downstream of the protospacer sequence in the DNA (Figure 2A). These PAM motifs appear 
on average every 8 base-pairs (bp) in the human genome (Cong et al., 2013), which usually 
offers plenty of options to target a specific locus. The DSB will then be introduced 3 bp 
upstream of the PAM sequence. 
Earlier site-specific nucleases that were used for genome editing, including zinc finger 
nucleases (ZFNs), transcription activator-like effector nucleases (TALENs) and 
meganucleases, required complex protein engineering to customize binding properties of the 
nuclease to the target locus (reviewed in Hsu et al., 2014). In contrast, the specificity of the 
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CRISPR system is solely based on complementary base pairing between nucleic acids that 
can easily be modified. This simplicity has made the CRISPR system rapidly into the leading 
tool for genome editing. 
 
1.1.3 Exploiting cellular DNA repair mechanisms for genome editing 
DNA DSBs are repaired by two main pathways: non-homologous end joining (NHEJ) or to a 
lesser extent homology-directed repair (HDR) (Rouet Philippe et al., 1994). The NHEJ pathway 
directly fuses two DNA ends together and typically results in different types of insertions or 
deletions (InDel) of usually 1-10 bp around the cut site (Mali et al., 2013; Paquet et al., 2016). 
For genome editing purposes, non-specific InDels that cause frameshift mutations can be used 
for gene knock-outs through premature stop codons on both alleles. The HDR pathway 
typically uses the homologous sister chromatid as template for errorless repair, but the 
pathway can also be exploited to introduce specific changes by providing an exogenous repair 
template, such as a single-stranded oligodeoxynucleotide (ssODN), that carries the desired 
edit with homology arms around the break site (Figure 2B) (Mali et al., 2013).  
 
 
Figure 2: Principle of genome editing using the CRISPR/Cas9 system. (A) The Cas9 nuclease/sgRNA 
complex binds to a specific locus in the DNA through complementary base-pairing between the spacer 
sequence (light green) of the sgRNA and the protospacer sequence (yellow) in the DNA, with the PAM 
sequence (purple) ‘NGG’ directly downstream of the target sequence. A DSB (scissors and red triangle) 
is then introduced by the Cas9 nuclease 3-4 nucleotides upstream of the PAM sequence. (B) CRISPR-
induced DSBs are mainly repaired in one of two ways: In the NHEJ pathway (top), both loose ends of 
the DSB are reconnected, which can result in non-specific small InDels at the cut site. Alternatively, to 
insert specific bp changes, one can exploit the cells intrinsic HDR pathway (bottom). Here, a repair 
template, e.g., a ssODN, carrying the desired bp changes can be supplied, which are then integrated 




1.2 Using induced pluripotent stem cells to generate in vitro models of human disease 
Another groundbreaking discovery that has revolutionized biomedical research was made a 
few years before the adaptation of the CRISPR system for genome editing: in 2008, Takahashi 
and Yamanaka described the reprogramming of mouse fibroblasts into cells that closely 
resemble embryonic stem cells (ESCs) by introduction of four specific exogenous factors: 
Oct3/4, Sox2, c-Myc, and Klf4. Hence, they called these cells induced pluripotent stem cells 
(iPSCs) (Takahashi & Yamanaka, 2006). A follow-up study one year later then reported that 
the same factors can also be used to reprogram human fibroblasts (Takahashi et al., 2007).  
In defined culture conditions, these iPSCs maintain their pluripotent state and can divide 
indefinitely, but the development of in vitro differentiation protocols also enables the generation 
of various somatic cell types from the same iPSC source. This is a great opportunity for 
disease-oriented research, as it allows studying phenotypes in different human cell types that 
are directly affected in patients. Especially research on diseases where the supply of affected 
cells is highly limited, such as neurodegenerative diseases, have greatly benefited from the 
iPSC technology: versatile protocols for the differentiation of brain cell types have been 
developed  (reviewed in McComish & Caldwell, 2018) and are already widely applied to 
investigate different disease mechanisms (reviewed in TCW, 2019). 
The generation of iPSCs eliminates ethical concerns about extraction of ESCs from fertilized 
embryos and additionally provides a sheer endless supply of cells that harbor different genetic 
backgrounds. This is highly useful to study diseases, as patient-derived iPSCs can be 
compared to iPSC lines from heathy controls. One caveat of this approach is, however, the 
high genetic variation between donors. These can either mask phenotypic effects of the 
mutation of interest or lead to non-specific phenotypes. For this reason, the CRISPR system 
provides an ideal addition to iPSC research: genetic modification to correct or introduce 
disease-associated mutations enables the generation of matching isogenic control lines, which 
allows studying the direct effects of genotypic changes in a homogenous background 
(Figure 3).  
 
 
Figure 3: Overview of generating human in vitro disease models using CRISPR-edited iPSCs.  
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The approach of using CRISPR-edited iPSCs for the generation of in vitro disease models is 
now widely used with the goal to unravel molecular disease mechanisms and to identify novel 
drug targets (Hockemeyer & Jaenisch, 2016). Genome editing of stem cells, however, is very 
challenging and hampered by low efficiencies, which requires the implementation of protocols 
for human iPSCs (Kwart et al., 2017) and also the development of new strategies to increase 
efficiency and versatility of the CRISPR/Cas9 system.  
 
1.3 Enhancing the efficiency of precise genome editing by the CRISPR/Cas9 system 
As described above, CRISPR-induced DSBs in the genomic DNA are typically repaired by the 
NHEJ pathway, which leads to non-specific InDels at the cut site. Correction or insertion of 
specific disease-causing mutations, however, requires precise editing using the HDR pathway, 
which is usually much less active. This research field therefore greatly benefits from new ideas 
that are contributed by inventive scientists to further advance the development of genome 
editing (reviewed in Pickar-Oliver & Gersbach, 2019). Some of these strategies include 
developing general guidelines for accurate gene editing, increasing the efficiency of precise 
gene editing in particular, identifying and engineering new CRISPR variants as well as 
developing new gene editing technologies. These points will be outlined in more detail in the 
following. 
 
1.3.1 Identifying fundamental principles for precise CRISPR editing 
A study from Paquet et al. established fundamental guidelines to enable efficient and precise 
knock-in of homozygous and heterozygous mutations using the CRISPR/Cas9 system (Paquet 
et al., 2016): first, they showed that it is necessary to inhibit Cas9 from re-cutting and 
destroying the locus after a successful edit has been made, which can be done by introducing 
silent blocking mutations that alter the PAM sequence or gRNA recognition site. If introducing 
silent mutations is not possible or desired, a two-step editing process termed ‘CORRECT’ may 
be applied for scarless genome editing. Furthermore, the authors characterized an inverse 
relationship between distance of Cas9 cleavage site and mutation site with the efficiency of 
genome editing. This distance effect can be used to guide zygosity of the introduced edit. 
 
1.3.2 Increasing the prevalence of DSB repair by the HDR pathway 
One of the main challenges that researchers face to perform precision editing is that the NHEJ 
pathway is usually more efficient for DSB repair than the HDR pathway. However, only the 
latter one can be used to introduce specific changes. Therefore, many different strategies were 
developed to increase the rate of repair by HDR (reviewed in Danner et al., 2017). Some of 
these strategies include suppression of key NHEJ factors by small molecules (Chu et al., 2015; 
Maruyama et al., 2015) or synchronization of the cell cycle together with delivery of pre-
assembled Cas9 ribonucleoprotein (RNP) complexes to enhance nuclease activity in stages 
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when the HDR pathway is most active (Lin et al., 2014). However, these approaches may 
interfere with the general cellular DNA damage response and could therefore lead to unwanted 
changes at loci other than the targeted site. Less invasive strategies were therefore developed 
that are restricted to the gene editing components itself, e.g., rational design of repair templates 
(Richardson et al., 2016), or cell cycle-dependent posttranslational regulation of Cas9 
(Gutschner et al., 2016). 
 
1.3.3 Identification of new CRISPR systems 
CRISPR systems are adaptive defense mechanisms that are widespread in bacteria and 
archaea (Wiedenheft et al., 2012). Given the fact that these organisms are highly diverse and 
dynamic, also different CRISPR systems have evolved over time that are now classified into 
different classes, types and subtypes (Makarova et al., 2020). The Cas9 nuclease that was 
first used for genome editing purposes - and is still the most widely used variant today - was 
originally isolated from the pathogen Streptococcus pyogenes (SpCas9) and belongs to the 
class II CRISPR systems (Jinek et al., 2012). This class is characterized by the presence of 
one single-component effector protein, which make these systems very useful for genome 
editing purposes. In addition to SpCas9, more Cas proteins from different organisms have 
been identified, e.g., Cas12a, CasX and Casφ, which all have unique features in comparison 
to Cas9 in regard to PAM requirement, size, DNA cleavage mechanisms and/or targeting 
specificity, which make them promising candidates to help broaden the scope of genome 
editing applications (Liu et al., 2019; Pausch et al., 2020; Zetsche et al., 2015). Another 
improvement was the development of engineered Cas9 protein versions that have altered PAM 
requirements (Kleinstiver, Prew, Tsai, Nguyen, et al., 2015; Kleinstiver, Prew, Tsai, Topkar, et 
al., 2015). These greatly help to further expand the range of targetable sequences. 
 
1.3.4 Development of new CRISPR-based editing technologies 
Researchers aiming to do precise gene editing are often faced with inadvertent side-effects 
caused by DSB induction (see below) as well as high rates of unwanted InDel mutations at the 
target locus. Moreover, given that HDR editing is only active in the S and G2 phase of the cell 
cycle, this approach is restricted to actively dividing cells. To overcome these limitations of the 
CRISPR/Cas9 system to some extent, the lab of David Liu has developed new technologies 
for gene editing in recent years, called base editing and prime editing (reviewed in Anzalone 
et al., 2020). Both systems use a Cas9 version that is mutated at one nuclease domain yielding 
‘nickase’ Cas9, which introduces only single-strand breaks (SSB) into genomic DNA. For base 
editors, a deaminase is fused to Cas9 that can initiate the direct conversion of one base to 
another (C•G to T•A base pair substitution for cytidine deaminases (Komor et al., 2016) or A•T 
to G•C for adenosine deaminases (Gaudelli et al., 2017)). For prime editing, a modified prime 
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editing guide RNA (pegRNA) both guides to a specific locus and also carries the desired edit, 
which is copied and inserted into the locus by a reverse transcriptase that is fused to Cas9 
(Anzalone et al., 2019) (Figure 4). This technique - unlike base editing - does not only enable 
base substitutions, but also insertions and deletions at the target locus. In short, base editing 
and prime editing enable DSB-free and template-free editing with much lower rates of 
unwanted side-products. 
 
      
Figure 4: Overview of CRISPR-based technologies. In the original CRISPR/Cas9 approach, a sgRNA 
guides the Cas9 nuclease to a specific locus in the genomic DNA to introduce a DSB (left). For base 
editors, a nickase version of Cas9 (nCas9) introduces SSBs into the DNA, and a deaminase fused to Cas9 
deaminates cytosines upstream of the cut site, which initiates their conversion to thymines (or adenine 
to guanine substitution in case of adenine base editors; not shown). Additional uracil DNA glycosylase 
inhibitors (UGI) prevent base excision repair at this site to increase the efficiency of base editing 
(middle). For prime editors, a reverse transcriptase is fused to nCas9 that copies the desired edit, which 
is encoded in the pegRNA, into the locus (right). Image modified from Anzalone et al., 2020. 
 
With all the optimizations and developments described above, the CRISPR/Cas9 system has 
become an incredibly powerful tool for precise, efficient, and versatile gene editing. But it must 
be noted that gene editing applications do not only require the methods to be efficient, but they 
also need to be safe and accurate in order to generate reliable research models.  
 
1.4 CRISPR gene editing can induce collateral damage 
While genome editing using the CRISPR/Cas9 systems offers endless possibilities for various 
research fields, it is important to remember that this always requires the release of highly active 
molecular scissors into living cells to deliberately disturb the integrity of the genetic information. 
Optimally, this will only lead to introduction of the desired change at the target locus. However, 
genome editing can also be accompanied by a wide range of additional unwanted alterations, 
both at the target locus (on-target) and also at other genomic loci (off-target) that are often 
unpredictable (reviewed in Burgio & Teboul, 2020; Thomas et al., 2019). This observation is 
very unsettling, as specificity is of utmost importance in all genome editing applications: In 
experimental studies, edited cell lines or organisms need to be fully characterized to ascribe 
observed phenotypic changes to a specific change in the genomic sequence. For gene 
therapy, unnoticed genetic consequences could possibly lead to proto-oncogene activation 
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and hence threaten patient safety. These inadvertent genomic changes therefore need to be 
carefully investigated, which requires specific and dedicated detection tools. 
 
1.4.1 Off-target effects  
Soon after the discovery of the CRISPR/Cas9 system for genome editing, first reports about 
unwanted off-target effects were made (Fu et al., 2013; Hsu et al., 2013; Pattanayak et al., 
2013). These are changes in the genomic sequence that arise from Cas9 nuclease activity at 
sites other than the target locus, which usually share high sequence similarity with the gRNA 
sequence but can contain up to 5 mismatches. Although a perfect prediction of off-target 
cleavage is not possible, several underlying principles were identified to predict affected sites:  
Off-target cleavage for one requires the presence of a PAM sequence, second, its likelihood 
decreases with number of mismatches and third, mismatches are less tolerated if they are 
more proximal to the PAM site. Furthermore, many researchers started to focus on developing 
new experimental methods to either minimize occurrence of off-target effects from the 
beginning or to develop sensitive methods for their detection after editing (reviewed in Naeem 
et al., 2020): first, it has become common practice to select sgRNAs for editing that have high 
specificity scores, i.e., with a low number and low probability of off-target cleavage sites as 
predicted by specific algorithms (Doench et al., 2016; Hsu et al., 2013). To facilitate editing 
design, such scores are now integrated into most gRNA selection tools, e.g., into CRISPOR 
(Concordet & Haeussler, 2018). Further strategies to improve editing specificity range from 
combining two Cas9 nickase enzymes that closely cut on opposite DNA strands to generate 
staggered DSBs (Ran et al., 2013), using truncated sgRNAs (Fu et al., 2014), or employing 
new engineered protein versions of Cas9 with higher fidelity, e.g., eSpCas9 (Slaymaker et al., 
2016), SpCas9-HF1 (Kleinstiver et al., 2016), HiFi Cas9 (Vakulskas et al., 2018). In addition, 
delivering Cas9 and sgRNA as purified and pre-assembled ribonucleoprotein (RNP) complex 
instead of both components being encoded on plasmids, was shown to decrease the time of 
Cas9 within the cell, thereby leading to lower off-target activity (Kim et al., 2014; Liang et al., 
2015). All of these methods, however, do not completely abolish off-target activity and 
therefore it is necessary to complement genome editing experiments with suitable OffTE 
detection methods afterwards: Sanger sequencing to genotype the top 5 to 10 off-target sites 
as predicted by above-mentioned algorithms can help to at least exclude the sites that are 
affected most likely. Alternatively, high-throughput whole-genome sequencing may also be 
performed. In addition, several methods have been developed to identify off-target sites 
experimentally in an unbiased way, with high specificity, and genome-wide. These include 
methods for in vivo detection, such as GUIDE-seq (Tsai et al., 2015) or DISCOVER-Seq 
(Wienert et al., 2019), as well as in vitro-based methods like CIRCLE-seq (Tsai et al., 2017) or 
CHANGE-seq (Lazzarotto et al., 2020). 
16 
 
Taken together, OffTEs have been at the focus of attention right after the discovery of 
CRISPR/Cas9 for genome editing. And although newly developed strategies have not yet led 
to perfect specificity, significant progress to tackle this problem has been made (Carroll, 2019; 
Cheng & Tsai, 2018). This situation, however, is much different for OnTEs that were described 
only very recently.  
 
1.4.2 On-target effects 
DNA DSBs, as induced by the Cas9 nuclease during genome editing experiments, are severe 
threats to the integrity of the genomic information. Cells have therefore developed diverse and 
robust mechanisms to repair this damage. On the one hand this is an advantage for genome 
editing purposes, as this leads to a wide range of different repair outcomes. On the other hand, 
these complex repair mechanisms can also lead to sequence changes that are usually not 
desired for genome editing, which are called OnTEs. These inadvertent changes can be large 
deletions, large insertions, complex rearrangements or also regions of copy-neutral LOH 
around the edited locus (Figure 5).  
 
 
Figure 5: CRISPR-induced OnTEs. Genome editing using the CRISPR/Cas9 system can induce unwanted 
alterations at the target locus, like (a) large deletions, (b) large insertions, (c) complex rearrangements 
or (d) regions of copy-neutral LOH. Example of HDR-mediated insertion of the APPSwedish (APPSwe) 
mutation, which leads to early-onset Alzheimer’s disease in patients (Haass et al., 1995). 
 
1.4.2.1 OnTEs are invisible in standard Sanger genotyping assays 
As described above, DSBs within the genomic DNA are usually repaired by high rates of NHEJ 
that leads to non-specific InDels at the edited site affecting only a few bp. But soon after the 
discovery of the CRISPR/Cas9 system, there have also been few isolated studies reporting 
InDels of over several hundred bp (Cradick et al., 2013; Parikh et al., 2015; Zuckermann et al., 
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2015). This phenomenon, however, was not directly investigated further, most likely because 
potential negative consequences were severely underestimated.  
Confirming successful genome editing usually involves genotyping the locus by PCR 
amplification of a few hundred bp around the target site followed by Sanger sequencing. This 
enables detection of small changes around the target site, but large insertions or deletions on 
one allele might be invisible if they are not amplified in the PCR reaction (Figure 6). Edited 
single cell clones or organisms might therefore easily be falsely classified as homozygously 




Figure 6: OnTEs are easily overlooked in conventional PCR genotyping. CRISPR genome editing can 
induce mono-allelic OnTEs such as large deletions, large insertions or complex rearrangements around 
the target site. If these overlap with one or both genotyping primer binding sites, the affected allele 
will not be amplified in the PCR reaction, hence, the Sanger sequencing trace only depicts the intact 
allele. Without the possibility of OnTEs in mind, this can easily lead to false interpretation of single cell 
clones as homozygously edited, although the locus is hemizygous. Example shows HDR-mediated 
insertion of the Alzheimer’s disease associated mutation APPSwe. 
 
Another inadvertent alteration that can be introduced by CRISPR editing has been described 
only very recently by Ikeda et al., which is copy-neutral LOH (Ikeda et al., 2018). In these 
cases, DSB repair leads to replacement of areas of one homologous chromosome by the other 
that can potentially extend from the cut site to the chromosome end (Figure 7) but might also 
affect smaller areas. These changes will in most cases also be missed in Sanger genotyping, 
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as PCR amplicons usually do not include heterozygous variants around the target locus that 
could reveal the LOH. 
All of these OnTEs might drastically alter gene expression of targeted or neighboring genes, 
which can easily lead to data misinterpretation if the unintended changes remain unnoticed.  
 
 
Figure 7: CRISPR genome editing may induce copy-neutral LOH. The repair of CRISPR-induced DSBs 
may lead to loss of chromosomal regions around the cut site that are replaced by the other 
homologous chromosome. This so-called copy-neutral LOH can affect small regions around the cut site 
(not shown) or entire chromosome arms. Example shows HDR-mediated insertion of the Alzheimer’s 
disease associated mutation APPSwe. 
 
1.4.2.2 Open questions surrounding the occurrence of OnTEs  
The problem of inadvertent alterations at the target locus after CRISPR-editing received more 
attention with a study from Shin et al. that reported the occurrence of large insertions and 
deletions at 17 sites in mouse zygotes (Shin et al., 2017). Next, a study by Kosicki et al. 
investigated if different cell lines are similarly affected and identified large deletions, insertions 
and complex rearrangements in mouse embryonic stem cells, mouse hematopoietic 
progenitors and an immortalized human cancer cell line (Kosicki et al., 2018). These and 
further studies clearly showed that OnTEs are a widespread problem after CRISPR editing in 
mice (Adikusuma et al., 2018; Owens et al., 2019), but the molecular mechanism leading to 
their occurrence remains largely unexplored (see discussion). Furthermore, it is not known if 
OnTEs also occur in clinically relevant human cells, such as iPSCs. Kosicki et al. identified 
OnTEs in human cells, but they only examined one locus and the cell line was immortalized, 
which is often accompanied by changes in DNA repair mechanisms. Previous studies also 
investigated OnTEs only after NHEJ-, but not HDR-mediated editing that has high relevance 
for disease-oriented research. All of these open questions highlight the need for more thorough 




1.4.2.3 Reliable OnTE detection methods are missing in the CRISPR field 
To prevent undetected OnTEs from leading to data misinterpretation, thorough on-target 
quality control analysis after CRISPR editing is needed. However, such measures are lacking 
in most genome-editing studies. This is in some part due to the low level of awareness of this 
issue in the CRISPR field, but also due to the lack of suitable detection methods: Previous 
studies investigating OnTEs have used primer-walk PCRs (Adikusuma et al., 2018; Kosicki et 
al., 2018; Owens et al., 2019; Shin et al., 2017), deep-sequencing-based methods (Adikusuma 
et al., 2018; Kosicki et al., 2018; Owens et al., 2019) or droplet digital PCR (Owens et al., 
2019), but these methods are laborious, expensive and/or require specialized expertise and 
equipment. Up to date, no specialized OnTE detection tools have been developed that allow 
low-cost and simple analysis of edited single cell clones or organisms after CRISPR editing. 
 
Taken together, although undetected OnTEs can severely affect the reliability of CRISPR-
based studies, this problem has been widely overlooked by the genome-editing community in 





2. Aim of this study 
The CRISPR/Cas9 system is an exceedingly powerful tool for genome editing, but its accuracy 
can be severely hampered by undetected OnTEs. These can be large deletions, insertions, 
complex rearrangements, or regions of LOH around the target site that are easily overlooked 
in standard quality control experiments like Sanger genotyping. OnTEs can strongly interfere 
with phenotype formation and thus, if being left unnoticed, affect the reliability of entire studies. 
Previous reports about frequent occurrence of OnTEs have created a lot of attention in the 
field, but they have mostly focused on mice edited by NHEJ. It is therefore still unclear if this 
problem also occurs in human cells subjected to HDR-mediated editing, which can be used to 
introduce precise changes, e.g., to study the mechanisms of disease-associated mutations. 
For this reason, one goal of this thesis was to investigate if also clinically relevant human iPSCs 
are affected. To determine how universally OnTEs occur, these iPSCs were edited at different 
disease-relevant loci by both, the NHEJ as well as the HDR pathway.  
Identifying and excluding edited cell lines that carry OnTEs should be a crucial step after 
genome editing. However, on-target quality control analysis is currently not typically performed 
by CRISPR users, mainly due the lack of simple detection tools. Another goal of this thesis 
was therefore to address this problem by developing a new technology for reliable detection 
of OnTEs. One central focus was hereby to circumvent the necessity for specialized knowledge 
and equipment in the entire workflow. Furthermore, the methods should be broadly applicable 
to different types of edits and edited cell lines or organisms likewise. We hope that this will 
facilitate widespread implementation of our quality control technology in the field and improve 




3. Research articles 
3.1 Detection of deleterious on-target effects after HDR-mediated CRISPR editing 
3.1.1 Summary 
In this study, we address occurrence of OnTEs in human iPSCs after HDR-mediated editing. 
First, we compared different tools that were used in previous studies for OnTE detection like 
primer-walk PCR, nearby SNP genotyping and standard quantitative PCR (qPCR) but noticed 
that these methods did not produce reliable results, can be very laborious and/or are not 
feasible at any given locus. We therefore saw a great need for improved detection tools in the 
CRISPR field and hence developed a new method that we called quantitative genotyping PCR 
(qgPCR). This method quantifies a 300-450 bp genotyping PCR reaction around the locus 
using a fluorescently labelled probe that matches the genotyping primers. This probe binds the 
PCR amplicon during the reaction, thereby enabling the quantification of target locus 
amplification in each PCR cycle. This allows determining the number of intact alleles at the 
target locus to identify single cell clones with large deletions, large insertions or complex 
rearrangements. Next, during our analysis we noticed that there are single cell clones that are 
affected by another even more unknown CRISPR-induced OnTE, which is copy-neutral LOH 
that can affect small regions around the cut site, but also entire chromosome arms. Here, we 
validated nearby SNP genotyping and SNP microarrays as reliable detection methods: In 
nearby SNP genotyping, zygosity of potential SNPs around the cut site are determined 
individually by Sanger sequencing. In contrast, SNP microarrays determine zygosity and copy 
number of SNPs on a genome-wide scale. 
Using our complete OnTE quality control workflow, we analyzed human iPSCs edited using 
the HDR pathway at different disease-relevant loci: We analyzed single cell clones after knock-
in of the Alzheimer’s disease-related mutations into the APP gene called ‘Swedish’ or ‘Iberian’. 
Furthermore, we analyzed single-cell clones after editing in a non-coding region close to the 
HDAC9 gene at the position of a lead SNP (rs2107595) associated with stroke and coronary 
artery disease, which was identified in a recent genome-wide association study (GWAS) (Malik 
et al., 2018). Strikingly, we identified frequent occurrence of different types of OnTEs in up to 
40% of edited clones independently of gRNA, locus, cell line, chromosome and coding region.  
Moreover, we illustrate deleterious consequences of OnTEs in an in vitro model of Alzheimer’s 
disease: When we differentiated human iPSCs carrying the APP ‘Swedish’ mutation into 
neurons, we saw that cells with OnTEs produced significantly lower levels of the APP protein 
and Aβ peptide. This may affect pathogenic phenotypes and thus prevent reliable disease 
modeling.  
Our results clearly indicate the widespread problem of OnTEs in human iPSCs after genome 
editing. To ensure locus integrity and prevent misleading results in CRISPR-based studies, we 
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CRISPR genome editing is a promising tool for translational research but can cause undesired editing out-
comes, both on target at the edited locus and off target at other genomic loci. Here, we investigate the occur-
rence of deleterious on-target effects (OnTEs) in human stem cells after insertion of disease-related muta-
tions by homology-directed repair (HDR) and gene editing using non-homologous end joining (NHEJ). We
identify large, mono-allelic genomic deletions and loss-of-heterozygosity escaping standard quality controls
in up to 40% of edited clones. To reliably detect such events, we describe simple, low-cost, and broadly
applicable quantitative genotyping PCR (qgPCR) and single-nucleotide polymorphism (SNP) genotyping-
based tools and suggest their usage as additional quality controls after editing. This will help to ensure the
integrity of edited loci and increase the reliability of CRISPR editing.
INTRODUCTION
CRISPR genome editing holds great promise for biomedical
research because it allows precise and efficient genomic modi-
fications for investigations of disease-associated variants, e.g.,
in disease-relevant human cell types derived from induced
pluripotent stem cells (iPSCs) (Hockemeyer and Jaenisch,
2016; Paquet et al., 2016). However, application of CRISPR
can be hampered by unwanted off- and on-target effects (Cheng
and Tsai, 2018; Thomas et al., 2019). Recent studies in mice
have described frequent occurrences of large deletions and
complex rearrangements at CRISPR-edited loci after repair by
non-homologous end joining (NHEJ) (Adikusuma et al., 2018;
Kosicki et al., 2018; Owens et al., 2019; Shin et al., 2017). It is
currently unclear whether such alterations also affect clinically
relevant human cells, such as iPSCs, because repair pathways
involved in CRISPR editing are differentially regulated (MacRae
et al., 2015), as indicated, for example, by shorter human gene
conversion tracts (Paquet et al., 2016). One report identified
on-target effects (OnTEs) at a single locus in an immortalized hu-
man cell line edited using stable overexpression of Cas9 and a
guide RNA (gRNA) (Kosicki et al., 2018) but did not address ef-
fects of transient expression of CRISPR machinery currently
used in most editing protocols. Importantly, to our knowledge,
it has not been investigated whether deleterious OnTEs also
occur in cells edited by homology-directed repair (HDR) to intro-
duce specific base changes, which has high relevance in disease
research and gene and cell-replacement therapies. HDR- and
NHEJ-edited clones are usually identified by PCR amplification
of a few hundred bases around the edited locus, followed by
Sanger sequencing (Kwart et al., 2017), but such genotyping
will fail to identify clones with large, mono-allelic insertions or de-
letions overlapping with genotyping primer-binding sites.
Instead, because the alterations prevent amplification of the
affected allele, such hemizygous clones will appear to be homo-
zygously edited (Figure 1A). Even though false identification of
homozygously edited clones can corrupt the reliability of entire
studies, tests for such deleterious OnTEs are still lacking in
most genome-editing studies. Some reports have applied
primer-walk PCR (Adikusuma et al., 2018; Kosicki et al., 2018;
Owens et al., 2019; Shin et al., 2017), PacBio or another deep-
sequencing method (Adikusuma et al., 2018; Kosicki et al.,
2018; Owens et al., 2019), or droplet digital PCR (Owens et al.,
2019) to detect large on-target alterations, but these methods
are expensive, laborious, or require specific expertise and equip-
ment. Here, we investigated whether large, mono-allelic dele-
tions or insertions occur in human iPSCs after HDR-mediated
CRISPR genome editing and developed quantitative genotyping
PCR (qgPCR) as a simple and broadly applicable tool for their
reliable detection. Strikingly, we identify these OnTEs in up to
40% of iPSC clones edited via HDR with CRISPR/Cas9 at
different loci and demonstrate deleterious effects on phenotype
formation in an Alzheimer’s disease iPSC line. Extending on an
earlier study (Ikeda et al., 2018), we also describe large regions
of copy-neutral loss-of-heterozygosity (LOH) upon HDR-medi-
ated editing in 8%–40% of clones and validate Sanger
sequencing and microarray-based tools for LOH detection.
Lastly, we investigated occurrence of large on-target deletions
after NHEJ-mediated CRISPR editing using qgPCR and found
the loss of one allele in 50% of apparently homozygous clones.
Cell Reports 31, 107689, May 26, 2020 ª 2020 The Author(s). 1




Analysis of OnTEs in HDR-Edited iPSC Clones by SNP
Genotyping and PCR Primer-Walking Yields
Inconsistent Results
To explore the incidence of deleterious OnTEs in CRISPR-edited
iPSCs, we analyzed 17 clones with an apparently homozygous
knock-in of the APP Swedish (APPSwe) mutation generated using
plasmid-based editing (Paquet et al., 2016; Figure 1A). APPSwe
causes early-onset Alzheimer’s disease in patients and is used
in many disease models. We reasoned that large, mono-allelic
alterations could be identified by genotyping single-nucleotide
polymorphisms (SNPs) near the target site that we identified to
be heterozygous before editing. Large deletions or insertions in
this region would prevent amplification of the aberrant allele in










Figure 1. Deleterious OnTEs after HDR-Mediated Genome Editing in Human iPSCs
(A) Sanger genotyping fails to identify mono-allelic deletions in APPSwe knockin clones.
(B) Hemizygous APPSwe clones can be detected by extending genotyping PCRs to nearby heterozygous SNP rs9976425.
(C) Primer-walk PCR identified a 2.8 kb deletion in APPSwe clone P1F11.
(D) Adding a qPCR probe to an existing genotyping PCR allows detection of reduced allele copy numbers by qgPCR.
(E) Allele copy numbers for two independent qgPCR assays reveal hemizygous clones with the loss of one allele after HDR knockin of APPSwe. Values were
normalized to the unedited parent cell line (A18944, n = 3). Data are represented as means ± SEM.
(F) Editing positions on chromosomes 21 and 7 at APP and HDAC9 loci.
(G) Identification of hemizygous clones edited at the APPIbe locus. Values were normalized to the unedited parent cell line (7889SA, n = 3). Data are represented as
means ± SEM.
(H) Identification of hemizygous clones edited at the HDAC9Mut locus. Values were normalized to the unedited parent cell line (7889SA, n = 3). Data are rep-
resented as means ± SEM.
(I) Two homozygous or hemizygous APPSwe clones were differentiated into cortical neurons, and the levels of total APP and secreted Ab were measured.
(J) Western blot of APP and tubulin indicates reduced APP expression in hemizygous clones.
(K) Quantification of (J) and biological replicates in Figure S2 (APP normalized to tubulin and means of homozygous clones on same gel, n = 4). Data are rep-
resented as means ± SEM. **p < 0.01, ***p < 0.001, one-way ANOVA. Dotted line indicates 50% of the means of homozygous clones.
(L) Ab secretion (normalized to total protein amount, n = 3) is also reduced in hemizygous clones. Data are represented as means ± SEM. **p < 0.01, one-way
ANOVA. Dotted line indicates 50% of the means of homozygous clones.




homozygosity of the SNP in Sanger sequencing. Indeed, SNP
rs9976425 appeared homozygous in five of 17 clones after edit-
ing, suggesting previously undetected mono-allelic changes
(Figure 1B; Table S1). To identify possible deletions, we per-
formed primer-walk PCRs up to 8 kb around the APPSwe locus
and increased the PCR extension times to detect insertions.
We identified additional products in two of the five clones iden-
tified by SNP genotyping, revealing a deletion of 2.8 kb in clone
P1F11 (Figure 1C) and an insertion of 4.1 kb in clone P1C4 (Fig-
ure S1; Table S1). Primer-walk PCRs were, however, not able to
resolve alterations in the remaining three clones identified in the
SNP assay, potentially because of PCR size limitations, illus-
trating the requirement for more reliable readouts. In addition,
both SNP genotyping and primer-walk PCRs are not universally
applicable because other loci may lack nearby heterozygous
SNPs or contain regions difficult to amplify by PCR.
qgPCR Reliably Detects Widespread Occurrence of
OnTEs in HDR-Edited iPSCs
An optimal assay should not only reliably identify deleterious
OnTEs but also work on every edited locus, integrate well into
existing gene-editing workflows, and be broadly applicable
with low requirements for special knowledge and equipment.
As genome-editing workflows usually contain a PCR for geno-
typing by RFLP and Sanger sequencing (Kwart et al., 2017),
we reasoned that the simplest way of testing for mono-allelic al-
terations would be to determine allele copy number using the
already established genotyping PCR.We addressed this by add-
ing a labeled probe to the existing genotyping primers for quan-
titative genotyping PCR (qgPCR). Edited single-cell clones with
large deletions or insertions will have higher cycle threshold
(Ct) values, corresponding to a reduced allele copy number at
the target site (Figure 1D; see design parameters in Figure S3).
To test this approach, we analyzed all 17 APPSwe clones by
qgPCR and confirmed the results with a second, independent
qgPCR assay. Compared with unedited parent cells, three
clones showed copy numbers corresponding to only one allele,
which all had been previously identified by SNP genotyping (Fig-
ure 1E; Table S1). Interestingly, two other clones with SNP ho-
mozygosity had normal allele numbers in both qgPCR assays,
suggesting a different OnTE, such as LOH (confirmed in further
analysis below). To investigate whether OnTEs occur indepen-
dently of gRNA, locus, chromosome, coding region, and cell
line, we repeated the analysis in a different iPSC line (7889SA;
Paquet et al., 2016), edited with a different gRNA for the APP Ibe-
rian mutation (APPIbe). We also analyzed a line edited in a non-
coding region near HDAC9 at rs2107595 (Figure 1F), a lead
SNP identified in a recent genome-wide association study
(GWAS) for stroke and coronary artery disease (Malik et al.,
2018). qgPCR analysis revealed frequent loss of alleles at both
loci and in both cell lines affecting two of five APPIbe and five
of 13 HDAC9Mut clones (Figures 1G and 1H). Again, primer-
walk PCRs failed to identify all affected clones. Similar to the
APPSwe results, SNP genotyping revealed additional clones
with SNP homozygosity but normal copy number, suggesting
LOH (Table S1, see further analysis below). In agreement with
previous studies (Owens et al., 2019; Shin et al., 2017), large de-
letions were preferentially located at sites withmicrohomologies,
suggesting involvement of the microhomology-mediated end-
joining (MMEJ) pathway (Table S2). Taken together, our data
show that deleterious OnTEs, such as large deletions or inser-
tions, occur in 18%–40% of CRISPR-edited human iPSCs and
that these undesired editing events can be reliably identified by
simple and universal qgPCR-based assays using already opti-
mized genotyping PCRs.
‘‘Standard Size’’ qPCR Assays Fail to Reliably Detect All
OnTEs
Because our qgPCR assays had amplicon sizes of around
350 bp, we also tested assays with amplicon sizes of around
150 bp, which is set as ‘‘standard’’ in most qPCR primer design
tools. However, these were not reliable because at least one
assay for each analyzed locus failed to identify all abnormal
clones (P1C4 for APPSwe, P2G2 for APPIbe, and P1A21 for
HDAC9; see Table S1 and Figure S3 for further details). In all
these cases, the edited loci appeared to have two normal alleles,
even though there were insertions or deletions present. These in-
sertions or deletions (indels) were missed because they did not
directly overlap with the cut sites, and, therefore, primers for
short PCRs were still able to bind and support locus amplifica-
tion. Hence, locus integrity cannot be reliably tested by ‘‘stan-
dard size’’ qPCRs but requires our longer qgPCR design.
OnTEs Affect Phenotype Formation in an iPSC-Based
Model of Alzheimer’s Disease
Most of the OnTEs we found in our HDR-edited lines caused
large changes on the genomic loci, which, in many cases, could
result in major changes in gene expression, unless the allelic
damage is compensated by the other allele. As most HDR-medi-
ated CRISPR editing is performed to insert or correct disease-
associated mutations, defective alleles may also have unin-
tended effects on disease modeling. To investigate potential
consequences of undesired OnTEs on protein expression in a
disease model, we differentiated APPSwe iPSCs with and without
mono-allelic alterations into cortical neurons and measured total
APP levels, as well as secretion of the APP cleavage product Ab
(Figure 1I). Hemizygous APP lines displayed a reduction in APP
expression and Ab secretion by about 50% (Figures 1J–1L and
S2). Such a reduction in Ab levels may reduce pathogenic effects
or even prevent formation of Alzheimer’s disease phenotypes in
an affected iPSC-based diseasemodel, thus illustrating potential
negative effects of undetected OnTEs on the reliability of studies
using CRISPR/Cas9 editing for disease modeling.
CRISPR/Cas9 Editing in iPSCs Can Cause LOH of Entire
Chromosome Arms
Our combined SNP genotyping and qgPCR analysis revealed
clones with normal allelic copy number but homozygosity at
nearby SNPs at all edited loci (APPSwe: P1G9 and P2E9; APPIbe:
P7H9; and HDAC9: P1E1; see Figures 1E, 1G, and 1H and Table
S1). We reasoned that this may result from repair of a large,
mono-allelic deletion by the homologous chromosome (Fig-
ure 2A). One previous report already indicated that copy-neutral
LOH can occur after HDR-mediated CRISPR editing (Ikeda et al.,
2018), but it is still unclear whether that is a general phenomenon
or restricted to the cell line or transgene-based editing approach




described in that study. To investigate the extent of LOH in our
edited iPSC lines, we identified SNPs that were heterozygous
in the unedited lines on both sides of the target locus up to
1 Mb away from the cut site and analyzed their zygosity after ed-
iting. In one clone, edited at APP on chromosome 21 (P1G9), and
another, edited at HDAC9 on chromosome 7 (P1E1), all tested
SNPs in the direction to the end of the chromosome were homo-
zygous (Figures 2B and 2C). Shorter regions were affected in the
remaining clones (Figure 2D). To determine whether the LOH
affected the entire chromosome arm in P1G9 and P1E1, we per-
formed whole-genome SNP genotyping using the Illumina global
screening array (GSA). Log R ratios showed normal copy num-
ber, but all heterozygous AB signals in B-allele frequency (BAF)
were lost in the affected areas, indicating copy-neutral LOH
from the cut site to the end of the targeted chromosome (Fig-
ure 2E). Taken together, our data indicate that LOH can occur af-
ter CRISPR/Cas9 editing, independent of chromosome, locus,
cell line, or editing method.
OnTEs Are Also Widespread in iPSCs Edited via the
NHEJ Pathway
Earlier work in mice and human cell lines indicated widespread
occurrence of OnTEs after CRISPR editing via the NHEJ
pathway (Adikusuma et al., 2018; Kosicki et al., 2018; Owens
et al., 2019; Shin et al., 2017), but it is currently unclear whether
OnTEs are also found in iPSCs, which differ in the regulation of
repair pathways (MacRae et al., 2015). We, therefore, analyzed
APPSwe clones edited via NHEJ using the same plasmid-based
CRISPR pipeline we also applied for HDR editing. We isolated
clones for which loss of a restriction site overlapping the cut
site indicated presence of indels and further analyzed the 28
clones in which presence of two alleles could not be shown by
detection of two distinct bands in gel electrophoresis after locus
PCR: 12 of these clones had differently edited alleles (i.e., double
peaks in Sanger sequencing), indicating presence of two alleles,
and this was confirmed by qgPCR in all cases (data not shown).
Strikingly, out of the remaining 16 clones with apparently homo-
zygous NHEJ editing (i.e., clean, single peaks in Sanger
sequencing), eight had an allele copy number of only ‘‘one’’ in
two independent qgPCR assays (Figure 3). These results were
consistent with results from our nearby SNP genotyping assay:
hemizygous clones identified by qgPCR were now homozygous
at SNP rs9976425 (data not shown). Thus, if researchers prefer-
entially select NHEJ clones with an apparently identical ‘‘clean’’
knockout on both alleles, they might have a 50% risk of using a






Figure 2. Detection of Copy-Neutral LOH after HDR-Mediated Genome Editing in Human iPSCs
(A) HDR editing may cause LOH, which can be detected via nearby SNP genotyping or SNP microarrays.
(B) Sanger sequencing traces of SNPs in control and edited clone P1G9 up to 1 Mb around the APPSwe cut site.
(C) Sanger sequencing traces of SNPs in control and edited clone P1E1 up to 1 Mb around the HDAC9 cut site.
(D) Sanger sequencing traces of SNPs in control and edited clones around the APPSwe (clone P2E9, top) or APPIbe (clone P7H9, bottom) cut sites.
(E) Log R ratio and BAF in control and edited clones for chromosome 21 (P1G9 edited for APPSwe) (left) and 7 (P1E1 edited at HDAC9) (right).





The recent CRISPR revolution has provided researchers with
powerful genome-editing tools that are widely applied in basic
and translational research and currently also cross barriers into
therapeutic applications of CRISPR-edited cells and editing
directly in patients (Fellmann et al., 2017). However, CRISPR
editing can cause unintended effects at the edited site and else-
where in the genome. Although off-target effects can be effi-
ciently detected with a variety of tools, the occurrence of OnTEs
has only been described recently in mice and an immortalized
human cell line. In these studies, OnTEs occurred frequently
upon genome editing via the NHEJ pathway, independent of
the applied CRISPR system (plasmid, RNP, and mRNA) (Adiku-
suma et al., 2018; Kosicki et al., 2018; Owens et al., 2019; Shin
et al., 2017). However, it has been unclear whether OnTEs also
occur in clinically relevant human stem cells or after editing by
HDR, which is used to introduce specific base changes. We
show that large, mono-allelic deletions and insertions occurred
in 18%–40% of human iPSC clones after HDR-mediated
CRISPR editing. These deleterious OnTEs appeared indepen-
dent of the targeted locus, gRNA, coding regions, or edited
cell line, suggesting widespread prevalence of on-target issues
in iPSCs and also in other organisms and systems. By differenti-
ating edited iPSCs with and without such unintended alterations
into cortical neurons and comparing levels of Alzheimer’s-dis-
ease-relevant Ab secretions, we demonstrate the drastic effects
unnoticed genomic alterations can have on studies using
CRISPR-edited cells. Confirming and extending on earlier work
in other systems, we also demonstrate the presence of OnTEs
in up to 50% of iPSCs edited via the NHEJ pathway.
Furthermore, we also observed the occurrence of copy-
neutral LOH after CRISPR editing, affecting entire chromosome
arms. Similar LOH has also been described in human pre-im-
plantation embryos edited by CRISPR to correct heterozygous
mutations by interhomolog recombination (Ma et al., 2017).
However, a major difference to our study is that the LOH allele
did not simply acquire the sequence of the other allele but, in
addition, contained the mutation introduced by the repair tem-
plate used for HDR. This difference indicates a more complex
repair scenario, in which it is not obvious that one allele acquired
the sequence of the other. Such loss of SNP heterozygosity may
potentially alter gene expression or expose effects of recessive
mutations, which could be detrimental, especially in edited hu-
man embryos and clinical applications of iPSCs. Our findings
highlight the need for technologies that reliably detect all un-
wanted OnTEs. Standard quality controls broadly performed in
the field, such as genotyping or karyotyping, will only detect
small events restricted to genotyping amplicons or very large
chromosomal aberrations, such as megabase-sized deletions,
translocations, and inversions, but miss the CRISPR-induced
OnTEs that we and others have revealed (Adikusuma et al.,
2018; Ikeda et al., 2018; O’Keefe et al., 2010; Owens et al.,
2019; Shin et al., 2017).
Moreover, high-density SNP arrays sometimes used for qual-
ity controls faithfully detect only larger deletions, inversions, and
LOH because their reliability increases with the number of
affected SNPs. LOH affecting single SNPs may be visible, but
the reliability of chip data for single SNPs is less than it is for
Sanger sequencing and often depends on the detection probe,
genomic location, etc. Copy-neutral inversions are usually invis-
ible in chip assays. Many of the OnTEs that we found were small,
affecting only a couple hundred to a few thousand base pairs.
Accordingly, these events overlapped with no, a single, or only
a few SNPs. Although such small events could be reliably de-
tected by qgPCR (deletions, insertions, and inversions) or our
Sanger sequencing-based assay (LOH), they could not be faith-
fully detected by the standard GWAS chip technology we used.
Using higher-density chips would not solve that problem
Figure 3. Widespread Formation of OnTEs after NHEJ-Mediated
Genome Editing in Human iPSCs
Allele copy numbers for two independent qgPCR assays reveal hemizygous
clones with the loss of one allele at the APPSwe locus after NHEJ editing (left);
50% of clones with apparently homozygous editing are affected. Indel sizes as
determined by Sanger sequencing (right).




because the detection is not limited by the overall number of
measured SNPs on the chip but by the number of measurable
affected SNPs around the edited locus. We, therefore, devel-
oped and validated assays based on qgPCR, Sanger
sequencing, and microarrays, which in combination allow reli-
able detection of OnTEs in iPSCs and other systems. We
selected these techniques because of their simplicity, low
cost, easy integration into existing workflows, universal applica-
bility for HDR- and NHEJ-mediated CRISPR editing in various
systems, and feasibility for non-specialist laboratories to allow
broad dissemination and acceptance in the field.We suggest us-
ing both qgPCR and nearby or global SNP genotyping as addi-
tional quality-control measures to increase the reliability of
CRISPR editing (see detailed workflow in Figure 4) in iPSCs
and other systems.
In this study, we focused on developing reliable assays for
OnTE detection to meet the urgent need of the CRISPR field
for thorough quality-control measures of edited cells and ani-
mals. However, future work should be aimed at not only detect-
ing these OnTEs but also understanding their biological roots
and reasons for occurrence, leading to strategies to avoid their
formation in the first place. This could be addressed by studying
(1) the locus-dependent influences, such as chromatin structure;
(2) the effects of genome-editing reagents, e.g., by using Cas9
nickase or another nuclease; (3) the effects of repair templates
by modulating the single-stranded oligodeoxynucleotides
(ssODN) design and orientation; and (4) the influences of other
repair pathways, e.g., by modulating the NHEJ or MMEJ path-
ways using knockdowns or specific inhibitors.
STAR+METHODS
Detailed methods are provided in the online version of this paper
and include the following:
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Figure 4. Workflow of Suggested Quality Control Experiments to Determine OnTEs after CRISPR Editing
Single-cell clones edited by CRISPR/Cas9 are first subjected to analysis by qgPCR to confirm unchanged allele numbers in edited clones and to exclude clones
with altered allelic copy number. To check clones for loss of heterozygosity (LOH), there are two possibilities: nearby SNP sequencing and SNPmicroarrays. Both
methods have their individual advantages, and the selection needs to be made according to the researchers’ needs: Nearby SNP sequencing is cheap and does
not require special equipment or expertise for analysis, whereas SNPmicroarrays are more expensive and involve complex data analysis. Local SNP sequencing
is more sensitive toward small regions of LOH that overlap with only a few SNPs, but identifying those heterozygous SNPs on both sides of the target site can be
laborious in contrast to a fast analysis by microarrays. Furthermore, SNP microarrays analyze SNP genotypes genome-wide and enable characterizing the
dimension of large regions of LOH, whereas nearby SNP genotyping is restricted to a few loci around the edited site. Taken together, a combination of qgPCR
analysis, and nearby SNP genotyping, and/or clone analysis by SNPmicroarrays should be conducted after CRISPR/Cas9 genome editing to ensure the integrity
of the edited loci.
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REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
APP-Y188 Abcam ab32136; RRID:AB_2289606
Tubulin Sigma T5168; RRID:AB_477579
Anti-Rabbit IgG (H+L), HRP Conjugate Promega W4011, RRID:AB_430833
Anti-Mouse IgG (H+L), HRP Conjugate Promega W4021, RRID:AB_430834




2x PrimeTime Gene Expression Master Mix IDT 1055772
20x human TERT TaqMan Copy Number Reference
Assay
ThermoFisher 4403316
OneTaq 2x Master Mix NEB M0486L
GeneRuler 100 bp Plus DNA ladder ThermoFisher SM0321
Critical Commercial Assays
NucleoSpin Tissue Kit Macherey-Nagel 740952
NucleoSpin Gel and PCR Clean-Up Kit Macherey-Nagel 740609
TOPO TA Cloning Kit for Sequencing ThermoFisher 450030
NucleoSpin Plasmid Kit Macherey Nagel 740588
NucleoSpin RNA/Protein Kit Macherey-Nagel 740933
MSD Human (6E10) Ab V-PLEX Kit Meso Scale Discovery K15200E
Experimental Models: Cell Lines
7889SA Paquet et al., 2016, NYSCF 7889SA
A18944 ThermoFisher A18945
Oligonucleotides
sgRNAs This paper Table S3
ssODNs for HDR-mediated editing This paper Table S3
Primers This paper Table S3
Recombinant DNA
MLM3636 a gift from K. Joung, Addgene 43860
pSpCas9(BB)-2A-Puro (PX459) V2.0 a gift from F. Zhang, Addgene 62988
pCas9_GFP a gift from K. Musunuru, Addgene 44719
Software and Algorithms
CRISPOR design tool Tefor http://crispor.tefor.net/
PrimerQuest design tool IDT N/A
PLINK N/A https://www.cog-genomics.org/plink/2.0/
Genome Studio 2.0 Illumina https://emea.illumina.com/techniques/
microarrays/array-data-analysis-
experimental-design/genomestudio.html
Ensembl Biomart tool Ensembl https://www.ensembl.org/info/data/biomart/
index.html
Primer3Plus Primer3Plus https://primer3plus.com
GraphPad Prism 8 GraphPad N/A
Other
Illumina Global Screening Array v2 genotyping chip Illumina 20030770






Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Dominik
Paquet (dominik.paquet@med.uni-muenchen.de).
Materials Availability
All unique/stable reagents generated in this study are available from the Lead Contact with a completed Materials Transfer
Agreement.
Data and Code Availability
All uncropped gels, raw qPCR data, APP and Abeta quantifications, Sanger sequencing reads and Illumina GSA chip data are avail-
able in Mendeley Data (https://dx.doi.org/10.17632/87kh5vj429.2).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
iPSC lines
iPSC experiments were performed in accordance with all relevant guidelines and regulations. Work with male line 7889SA (Paquet
et al., 2016) (NYSCF) was approved by the Rockefeller University Institutional Review Board after informed consent was obtained
from subjects by Coriell Institute. Female iPSC line A18944 was purchased from ThermoFisher (A18945).
CRISPR/Cas9 genome editing
Single guide RNAs (sgRNAs) were designed using the CRISPR design tool (http://crispor.tefor.net/). sgRNA sequences were cloned
into the BsmBI restriction site of plasmid MLM3636 (a gift from K. Joung, Addgene 43860). CRISPR editing was performed as
described previously (Paquet et al., 2016) using Cas9 plasmids pSpCas9(BB)-2A-Puro (PX459) V2.0 (a gift from F. Zhang, Addgene
62988) or pCas9_GFP (a gift from K. Musunuru, Addgene 44719). Repair oligos were either symmetric 100 bp ssODNs with the same
orientation as the gRNA sequence (APPSwe, (Paquet et al., 2016)) or asymmetric 107 bp ssODNs (71 and 36 bp, long arm on the PAM-
proximal side (Richardson et al., 2016)) with sequence complementary to the gRNA (APPIbe and HDAC9), and ordered as Ultramers
from IDT.
iPSC culture, electroporation and cortical differentiation
iPSCs were maintained on Vitronectin-coated (ThermoFisher A14700) cell culture plates and grown in Essential 8 Flex Medium
(ThermoFisher A2858501) at 37!C with 5% CO2. Prior to transfection, iPSCs were transferred to Geltrex-coated (ThermoFisher
A1413302) cell culture plates and grown in StemFlex Medium (ThermoFisher A3349401) containing 10 mM ROCK inhibitor (Selleck-
chem S1049) for two days. iPS cells were transfected by electroporation as described (Kwart et al., 2017). Briefly, two million cells
were resuspended in 100 mL cold BTXpress electroporation solution (VWR 732-1285) with 20 mg Cas9, 5 mg sgRNA plasmid, and
30 mg ssODN. Cells were electroporated with 2 pulses at 65 mV for 20 ms in a 1 mm cuvette (Fisher Scientific 15437270). After elec-
troporation, cells were transferred to Geltrex-coated 10 cm plates and grown in StemFlex Medium containing 10 mMROCK inhibitor.
Cells expressing Cas9 were selected either by sorting for GFP (Kwart et al., 2017) or selection with 350 ng/ml Puromycin dihydro-
chloride (VWR J593) for three consecutive days starting one day after electroporation (Steyer et al., 2018). Single-cell clone colonies
were picked and analyzed by RFLP assay, using NEB enzymes TfiI for APPSwe, DdeI for APPIbe, XmnI for HDAC9, and Sanger
sequencing as previously described (Kwart et al., 2017). Cortical neuron differentiation was performed using a dual-SMAD inhibi-
tion-based protocol as described (Paquet et al., 2016).
METHOD DETAILS
Genotyping assay design and copy number analysis by quantitative genotyping PCR (qgPCR)
Assays for qgPCR analysis of edited single-cell clones were designed using the IDT PrimerQuest design tool. Briefly, a 400-550 bp
region surrounding the edited locus was entered and the amplicon size range set to 300-450 bp. The edited site was selected as
excluded region for the probe to prevent overlap. If genotyping primers were available, the primer sequences were entered under
partial design input. Assays in which the probe was close to the edited site were favored. For copy number analysis, genomic
DNA (gDNA) was isolated with a NucleoSpin Tissue Kit (Macherey-Nagel 740952) according to manufacturer’s instructions and
60 ng were used for analysis. As we occasionally observed variation in gDNA integrities from stored gDNA samples we recommend
using fresh gDNA isolated at the same time from control and assayed clones. Freshly isolated gDNA was mixed with 2x PrimeTime
Gene Expression Master Mix (IDT 1055772), 20x human TERT TaqMan Copy Number Reference Assay (ThermoFisher 4403316) as
internal reference control, genotyping primers (0.5 pmol/ml) and the designed PrimeTime Eco Probe 50 6-FAM/ZEN/30 IBFQ (0.25
pmol/ml, HPLC-purified, IDT). The qgPCR reaction was run for 2 min at 50!C, 10 min at 95!C, followed by 40 cycles of 15 s at
95!C and 1 min at 60!C. Allele copy numbers were determined by ddCt calculation relative to internal TERT reference and unedited




control; values were multiplied by two to get total number of alleles. qgPCR experiments were performed in three independent tech-
nical replicates.
GSA Illumina Chip
gDNA from all iPSC lines to be analyzed was isolated with a NucleoSpin Tissue Kit and diluted to a concentration of 75 ng/ml. Whole-
genome genotyping was performed at the Helmholtz Zentrum M€unchen Genome Analysis Center (Neuherberg, Germany) using the
Illumina Global Screening Array v2 genotyping chip (Illumina, San Diego, California, USA). Single nucleotide polymorphisms (SNPs)
were called using the GenCall algorithm. All samples analyzed showed a sample call rate > 0.99. Gender checks were performed as
an additional quality control step using PLINK2 (https://www.cog-genomics.org/plink/2.0/). SNPs with a call rate < 0.9 were dis-
carded. All SNPswere filtered using a Hardy-Weinberg equilibrium p-value cutoff of 1E-4 and aGenTrain score cutoff of 0.7 to ensure
correct clustering (Guo et al., 2014). Log R Ratio and B Allele Frequency were extracted using Genome Studio 2.0 (Illumina, San
Diego, California, USA).
Genomic variant identification
Potential genomic variants within 5 kb around the edited loci were identified using the Ensembl Biomart tool (http://www.ensembl.
org//useast.ensembl.org/info/data/biomart/index.html?redirectsrc=//www.ensembl.org%2Finfo%2Fdata%2Fbiomart%2Findex.
html) with the following settings and filters: Ensembl variation 98 database, human Short Variants (SNPs and InDels excluding flagged
variants), respective chromosomewith a region of around 5kb around the edited site, global minor allele frequency > = 0.2. The flank-
ing sequence around the retrieved variants was downloaded from Ensembl and used in Primer3Plus (https://primer3plus.com/) to
design primers for SNP genotyping. Prior to Sanger sequencing, the amplicons were analyzed for size differences by agarose gel
electrophoresis to check for length polymorphisms. Heterozygosity of SNPs was confirmed by identification of double peaks in
Sanger sequencing in unedited versus edited iPSC. Heterozygous SNPs in a 1 Mb region around the edited loci were identified
by parsing data from a previous molecular karyotyping experiment performed in unedited parent lines using the Illumina bead array
HumanOmni2.5Exome-8 BeadChip v1.3 (Life & Brain GmbH, Bonn) (data not shown).
Primer-walk PCR
Primer-walk PCRs were performed with edited single-cell clones to identify aberrant PCR products with OneTaq 2xMaster Mix (NEB
M0486L) followingmanufacturer’s instructions. Primers with increasing distance to the cut site in steps of around 500 bpwere tested.
PCR products were analyzed by agarose gel electrophoresis with a GeneRuler 100 bp Plus DNA ladder (ThermoFisher SM0321). If
additional bands, not present in the unedited control cell line, were detected, PCR products were gel-purified using a NucleoSpin Gel
and PCR Clean-Up Kit (Macherey-Nagel 740609) followed by Sanger sequencing. If sequencing was not successful, PCR products
were TOPO cloned following manufacturer’s instructions (TOPO TA Cloning Kit for Sequencing, ThermoFisher 450030). Plasmids
with TOPO-cloned inserts were isolated using the NucleoSpin Plasmid kit (Macherey Nagel 740588) and Sanger sequenced.
Measurements of total APP and Amyloid-b
Total protein was extracted from differentiated neurons at DIV 35 with the NucleoSpin RNA/Protein Kit (Macherey-Nagel 740933) ac-
cording to manufacturer’s instructions, separated on 8% TRIS-Glycine hand-casted gels, transferred to nitrocellulose membranes
(Amersham Protran 0.45 NC, GE Healthcare), boiled for 5 min in PBS, and blocked for 1 h using 0,2% I-Block (ThermoFisher T2015)
with 0,1% Tween20 (Merck) in PBS. Primary antibodies (APP-Y188, Abcam ab32136, 1:4,000; Tubulin, Sigma T5168, 1:4000) were
diluted in blocking solution and incubated with the membrane overnight at 4!C. After three washes in PBS + 1% Tween20, HRP-
labeled secondary antibodies (Anti-Rabbit IgG (H+L), HRP Conjugate, Promega, W4011; Anti-Mouse IgG (H+L), HRP Conjugate,
Promega, W4021) were added for 1h and protein signals were detected using Pierce ECL Western Blotting Substrate kit (Thermo-
Fisher 32109), using a Fujifilm LAS4000 luminescence imager and band intensities quantified using ImageJ. For Ab measurements,
cell supernatant was conditioned for 5 days and experiments were performed in 3 biological replicates. Supernatants from experi-
ments collected at different time points were flash-frozen in liquid nitrogen and stored at "80!C. Secreted Ab1"38, Ab1"40 and
Ab1"42weremeasured withMSDHuman (6E10) Ab V-PLEX kits (Meso Scale Discovery) according to themanufacturer’s directions.
Ab values were combined to obtain total Ab and normalized to total protein levels from cell lysate determined by the Karlsson et al.
(1994) method, as described in the NucleoSpin RNA/Protein Kit.
QUANTIFICATION AND STATISTICAL ANALYSIS
No statistical methods were used to predetermine sample size and the experiments were not randomized. Experimental data was
analyzed for significance using GraphPad Prism 8. Multiplicity-adjusted p < 0.05was considered statistically significant. Significance
was analyzed by one-way ANOVA comparing themean of each columnwith themean of the control followed bymultiple-comparison
post-testing with Dunnett’s method. The analysis approaches have been justified as appropriate by previous biological studies, and
all data met the criteria of the tests. The investigators were not blinded to allocation during experiments and outcome assessment.
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Figure S1. Genotyping results and primer-walk PCRs in CRISPR-edited clones, related to Figure 1.  
(A) Sanger genotyping suggests homozygous HDR editing of APPSwe, APPIbe and HDAC9Mut in single-cell clones later 
identified to have mono-allelic deletions, insertions or LOH (see also Supplementary Table 1).  
(B) Primer-walk PCR identified alleles with insertions, deletions or inversions for APPSwe (top left), APPIbe (top middle), and 
HDAC9Mut clones (remaining 5 clones). L: DNA ladder, WT: wildtype. The wildtype allele is hardly visible in some clones, 





Figure S2. Quantification of APP expression in CRISPR-edited clones, related to Figure 1.  
Western blot images of biological replicates 2-4 with APP and β-Tubulin expression used for quantification shown in Figure 
1K. Loading controls (β-Tubulin) were run on the same blot as APP and quantitative comparisons were only performed 




Figure S3. Design of quantitative PCR assays for detection of allele copy numbers in CRISPR-edited iPSCs, related to 
Figures 1 and 3. (A) Design parameters and guidelines for qgPCR assays around inserted mutation(s) ‘M’. By using the same 
“base PCR” as for RFLP and Sanger sequencing, qgPCR assays on edited single-cell clones easily integrate into existing 
genome editing workflows.  
(B-D) Positions of two independent qgPCR assays around APPSwe (B), APPIbe (C) and HDAC9Mut (D) loci shown in Figure 1, 
with forward primer (fw), reverse primer (rv) and qPCR probe (Full primer names, as listed in Methods: APP_Swe_Gt…, 
APP_Ibe_Gt…, HDAC9_Gt_...).  
(E) ‘Standard’ short amplicon qPCR assays fail to detect aberrant clones: Allele copy numbers for two independent short 
amplicon qPCR assays reveal several hemizygous clones, but at each locus one aberrant clone is not detected by either one or 
both short assays (red box). All values normalized to unedited parent cell line (A18944 or 7889SA).  
(F) Overview of qPCR probe designs (top), position of primers (fw, rv) and probes for short qPCR assays 1+2 at APPSwe (full 
primer names, as listed in methods: APP_Swe_short…) (middle), and explanation of failed detection of insertion in clone 
P1C4 at APPSwe locus (bottom).  
(G) Overview of qPCR probe designs (top), position of primers (fw, rw) and probes for short qPCR assays 1+2 at HDAC9 
(full primer names, as listed in methods: HDAC9_short…) (middle), and explanation of failed detection of insertion in clone 
P1A21 at HDAC9Mut locus (bottom). 
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Short amplicon  




(2.4 kb upstream) 
Zygosity at 
rs1783016** 






 P1A5 2 2 heterozygous heterozygous not tested - 
APP
Swe








homozygous heterozygous no 
4.1 kb insertion, small 
deletions (Figure S1B) 
APP
Swe
 P1C8 2 2 heterozygous heterozygous not tested - 
APP
Swe
 P1D4 2 2 heterozygous heterozygous not tested - 
APP
Swe













 P1G4 2 2 heterozygous heterozygous not tested - 
APP
Swe








homozygous homozygous LOH until end 
of chromosome 
(Figure 2E) 
LOH ~1 Mb LOH by further SNP 
genotyping analysis (Figure 2B) 
APP
Swe
 P1H7 2 2 heterozygous heterozygous not tested - 
APP
Swe
 P2B3 2 2 heterozygous heterozygous not tested - 
APP
Swe





P2C5 1 1 homozygous heterozygous no 
not resolved, potentially 
very large deletion 
APP
Swe





P2E9 2 2 
homozygous heterozygous 
no LOH 
~2 kb LOH by further SNP  
genotyping analysis (Figure 2D) 
APP
Swe
 P2G7 2 2 heterozygous heterozygous not tested - 







Short amplicon  




(0.5 kb upstream) 
Zygosity at 
rs5843179* 








P2G2 1 2 homozygous homozygous ~ 79 kb LOH 
not resolved, potentially 
very large deletion and LOH 
APP
Ibe





P6G10 1 1 homozygous homozygous not tested 









P7H9 2 2 
homozygous homozygous 
~ 10 kb LOH LOH ~3 kb LOH by further SNP  
genotyping analysis (Figure 2D) 







Short amplicon  




(2 kb upstream) 
Zygosity at 
rs2717368*  











homozygous homozygous not tested 









P1A81 1 1 
2 PCR products of 
different length 
homozygous no 









P1E1 2 2 
homozygous heterozygous LOH until end 
of chromosome 
(Figure 2E) 
LOH ~1 Mb LOH by further SNP  





P1G3 1 1 homozygous homozygous no 
1.8 kb insertion, small 
deletion (Figure S1B) 
HDAC9
Mut
 P2B3 2 2 heterozygous heterozygous not tested - 
HDAC9
Mut





P2C4 1 1 
2 PCR products of 
different length 
homozygous not tested 









P2D5 1 1 homozygous homozygous not tested 




 P2E6 2 2 heterozygous heterozygous not tested - 
HDAC9
Mut
 P2E12 2 2 heterozygous heterozygous no - 
 
* PCR for SNP genotyping was spanning the cut site 
** PCR for SNP genotyping was not spanning the cut site 
 
 






, related to Figures 1 and 2. Data of 
altered clones shown in indicated figures, other data not shown. 
 
Locus Clone ID Retained l Deleted l Retained Homologous bases 
APP
Swe
 P1C4 Insertion N/A 
APP
Swe
 P1F11 AGACAGTTCClGGATGTGAAT………………TCCCAAATCClTGACCTATAA 3 
APP
Ibe
 P6G10 CATCACCAAGlGTGATGACGA………………GAAAGCCAAGlATTCTTGTGC 5 
HDAC9
Mut
 P1A21 (1st Deletion) TTCTTTGTAClGTACTGTGGC………………TAAAAAGTAClTCATTGAGAA 4 
HDAC9
Mut
 P1A21 (2nd Deletion) AAAAGATGTGlGGATTTTTAT………………TCATATCCTGlTAATTTTTCA 2 
HDAC9
Mut
 P1A21 (3rd Deletion) CAAAAATTTTlGCCAAATTGA………………TAAATATTTGlGCCAACTTTT 5 
HDAC9
Mut
 P1A81 Complex changes with duplication and inversion N/A 
HDAC9
Mut
 P1G3 Insertion N/A 
HDAC9
Mut
 P2C4 GGATTGAAGAlCATATCCCTC………………GCAAAAAAGAlATGTACAAGC 4 
HDAC9
Mut
 P2D5 Complex changes with duplication and inversion N/A 
 
Table S2. Microhomologies are prevalent at large deletion sites in CRISPR-edited iPSCs, related to Figure 1. Sequences 
around deletion sites with microhomologies (indicated with red letters) suggesting involvement of the MMEJ pathway. Black 
bars indicate sites of fusion between flanking regions, intervening part is deleted.  
41 
 
3.2 Simple and reliable detection of CRISPR-induced on-target effects by qgPCR 
and SNP genotyping 
3.2.1 Summary 
In this protocol, we provide a detailed description for reliable OnTE detection after CRISPR-
editing, based on the tools that we have established in our first study described above. All 
steps are described with substantial detail as well as suggestions for troubleshooting to also 
enable conduction of these methods by less experienced users. Furthermore, we extend 
protocol and discussion to genome-edited organisms that might also be affected by OnTE 
occurrence.  
The protocol covers six main parts: 1) extraction of genomic DNA from edited samples for 
further analysis, 2) optimization of a genotyping PCR, 3) design of a qgPCR assay, 4) analysis 
of edited cells and organisms by qgPCR, and LOH analysis by 5) nearby SNP sequencing or 
the alternative option 6) SNP microarrays. 
For the first step, we provide two different options: harvesting of cells from edited clones or 
collection of tissues from edited organisms followed by extraction of genomic DNA that will be 
used in the subsequent analysis. Next, we describe optimization of a 300-450 bp genotyping 
PCR reaction around the cut site by comparing the efficiency of different primer combinations. 
The third step involves designing an internal probe that is compatible with the genotyping PCR 
primers, which should then be ordered as fluorescently labelled oligo to enable quantification 
in the following qgPCR analysis. In the fourth step, we describe analysis of edited cells or 
organisms by qgPCR, including preparation of the reaction, running it on a standard qPCR 
machine and finally correlating the resulting threshold cycle (Ct) values with the number of 
intact alleles at the target locus to exclude samples with large deletions, insertions, or complex 
rearrangements. Nearby SNP genotyping in the fifth step starts with retrieving a list of 10-20 
SNPs around the edited locus from an online database. Genotyping of these SNPs in the 
unedited parent cell line or organism should be performed until at least one heterozygous SNP 
is identified on both sides of the target locus, which is followed by validation of zygosities after 
editing. For the alternative option for LOH analysis by SNP microarrays, we start with a 
description how to identify suitable microarray chips, which should have a sufficient SNP 
coverage around the target site. Subsequent steps are based on specific equipment like a 
hybridization oven, pipetting robots and an iScan scanner. Data analysis involves extracting B 
allele frequencies for SNP zygosities and Log R ratios for copy numbers for each SNP to 
identify regions of LOH. Edited single cell clones or organisms that show any abnormalities in 
the assays, should be excluded from further experiments due to OnTEs.  
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Simple and reliable detection of CRISPR-induced
on-target effects by qgPCR and SNP genotyping
Isabel Weisheit1,2, Joseph A. Kroeger1,2, Rainer Malik1, Benedikt Wefers 3,4, Peter Lichtner5,
Wolfgang Wurst3,4,6,7, Martin Dichgans1,3,7 and Dominik Paquet 1,2,7✉
The recent CRISPR revolution has provided researchers with powerful tools to perform genome editing in a variety of
organisms. However, recent reports indicate widespread occurrence of unintended CRISPR-induced on-target effects
(OnTEs) at the edited site in mice and human induced pluripotent stem cells (iPSCs) that escape standard quality
controls. By altering gene expression of targeted or neighbouring genes, OnTEs can severely affect phenotypes of
CRISPR-edited cells and organisms and thus lead to data misinterpretation, which can undermine the reliability of
CRISPR-based studies. Here we describe a broadly applicable framework for detecting OnTEs in genome-edited cells and
organisms after non-homologous end joining-mediated and homology-directed repair-mediated editing. Our protocol
enables identification of OnTEs such as large deletions, large insertions, rearrangements or loss of heterozygosity (LOH).
This is achieved by subjecting genomic DNA first to quantitative genotyping PCR (qgPCR), which determines the number
of intact alleles at the target site using the same PCR amplicon that has been optimized for genotyping. This combination
of genotyping and quantitation makes it possible to exclude clones with monoallelic OnTEs and hemizygous editing, which
are often mischaracterized as correctly edited in standard Sanger sequencing. Second, occurrence of LOH around the
edited locus is detected by genotyping neighbouring single-nucleotide polymorphisms (SNPs), using either a Sanger
sequencing-based method or SNP microarrays. All steps are optimized to maximize simplicity and minimize cost to
promote wide dissemination and applicability across the field. The entire protocol from genomic DNA extraction to OnTE
exclusion can be performed in 6–9 d.
Introduction
CRISPR–Cas9 technology is revolutionizing biomedical research because it allows researchers to
directly and specifically modify genes in many different organisms, including human cells and
patients1–4. New protocols for genome editing are constantly generated and improved to further
increase efficiency and applicability5,6. In the course of this advancement, the technology has been
widely used to generate models of human disease in, e.g., mice or clinically relevant induced
pluripotent stem cells (iPSCs). However, CRISPR editing is not always precise and can lead to
inadvertent alterations in the edited genome, both at the edited site (on-target) and at other genomic
loci (off-target). Although the problem of off-target effects has been well recognized and addressed
with reliable detection technologies in the field5,7,8, efficient and broadly applicable tools for detection
of on-target effects (OnTEs) are still lacking. As we and others have recently shown, OnTEs can occur
at high frequency in mouse and human cells, with up to 40% of edited clones affected in human
iPSCs9–13. In this article we describe a procedure to efficiently detect OnTEs and ensure locus
integrity after CRISPR editing.
Development of the protocol
In our recent study13 we revealed frequent occurrence of OnTEs, such as large deletions, large
insertions, complex rearrangements and loss of heterozygosity (LOH) caused by CRISPR genome
editing in human iPSCs. These OnTEs occurred in up to 40% of clones edited to introduce targeted
mutations via the homology-directed repair (HDR) pathway and to a similar degree in clones with
apparently homozygous frameshift edits to generate knockouts via the non-homologous end joining
1Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany. 2Graduate School of Systemic Neurosciences,
LMU Munich, Planegg-Martinsried, Germany. 3German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany. 4Institute of
Developmental Genetics (IDG), HelmholtzZentrum München, Neuherberg, Germany. 5Core Facility NGS, HelmholtzZentrum München, Neuherberg,
Germany. 6Technische Universität München-Weihenstephan, Neuherberg, Germany. 7Munich Cluster for Systems Neurology (SyNergy), Munich,
Germany. ✉e-mail: dominik.paquet@med.uni-muenchen.de


















(NHEJ) pathway. Earlier work also demonstrated presence of OnTEs in CRISPR-edited mice and cell
lines9–12, and it is therefore conceivable that OnTEs are a widespread problem relevant for CRISPR
editing in many organisms (Fig. 1a). Highlighting the importance of their detection, we showed that




























































































































Fig. 1 | CRISPR–Cas9 genome editing induces deleterious OnTEs that can be detected by qgPCR and SNP genotyping in a simple and reliable
manner. a, CRISPR editing can induce unintended OnTEs such as large deletions, large insertions, complex rearrangements or regions of copy-neutral
loss of heterozygosity (LOH) around the target locus in human cells, mice and other organisms during HDR- or NHEJ-mediated editing. b, OnTEs often
escape standard quality controls such as Sanger genotyping: large alterations might prevent primer binding at the affected allele, which leads to
seemingly homozygous sequencing traces (middle panel). Regions of LOH are also routinely missed as there are usually no heterozygous SNPs
present within the genotyping PCR (right panel). ssODN, single-stranded oligodeoxynucleotide. c, qgPCR analysis can be easily integrated into existing
genome-editing workflows by adding a fluorescently labeled probe to the established genotyping PCR and measuring copy numbers by qPCR.
Hemizygous clones with only one intact allele will be revealed by increased Ct values. RFLP, restriction fragment length polymorphism. d, qgPCR allows
detection of monoallelic large deletions (left), large insertions (middle) and complex rearrangements (right) that prevent amplification of the affected
allele. e, LOH is detected by Sanger sequencing of nearby heterozygous SNPs or SNP microarrays that investigate SNP zygosities and copy numbers
genome-wide. f, Nearby SNP sequencing involves identifying heterozygous variants around the target locus in unedited cell lines and genotyping these
in edited cell lines. c and e are modified from ref. 13.
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models13. We therefore developed and validated assays for reliable detection of OnTEs based on
quantitative PCR (qPCR), Sanger sequencing and single-nucleotide polymorphism (SNP) micro-
arrays. Rather than developing a complex technology accessible only by specialist laboratories, we
reasoned that the best way to perform OnTE detection is with a simple and affordable technology that
is broadly applicable to established editing workflows. We therefore set out to develop a protocol that
is easy to implement by every laboratory performing CRISPR genome editing with minimal
requirements for specialized machinery. The entire workflow of OnTE detection, including analysis of
LOH, can be performed using standard molecular biology equipment such as PCR and qPCR
machines and a gel electrophoresis setup. Alternative LOH detection by SNP microarrays can be
performed if relevant equipment or access to a core facility is available. Analysis of all steps requires
only freely available software. We hope this will help to ensure wide dissemination of OnTE quality
control in the genome editing field.
OnTEs can be large deletions, large insertions or other complex rearrangements at edited genomic
loci. Standard genotyping by PCR and Sanger sequencing will only detect small changes within the
PCR amplicon; however, larger events are missed if they only occur on one allele. While the unaf-
fected allele will display the desired edit, the aberrant allele will be invisible when a loss of primer
binding sites prevents amplification and sequencing. In addition, it has been described very recently
that CRISPR editing can also cause LOH, i.e., the replacement of potentially large areas of one
homologous chromosome by the other13,14. This type of OnTE is also invisible in standard geno-
typing assays (Fig. 1b), except in rare cases where heterozygous SNPs are present in the PCR
amplicon on both sides of the edit. To exclude LOH or the complete loss of an edited allele, we
developed an OnTE detection framework based on a modified application of two basic techniques
that are available in most molecular biology laboratories: qPCR and genotyping of SNPs.
We first describe quantitative genomic PCR (qgPCR), a new method in which a 300–450 bp
genotyping PCR of the region around the edited site is used to confirm presence of two correctly
edited alleles. This step involves designing a fluorescently labeled probe that binds to the PCR
amplicon according to specific design principles described in our protocol, extracting genomic DNA
(gDNA) from a clonal population of edited cells or gene-edited organisms, and performing and
analyzing qgPCR (Fig. 1c). In the qgPCR reaction, the probe allows real-time monitoring of target
locus amplification rates during each PCR cycle. Calculation of gene copy numbers can then be
performed by determining the threshold cycle (Ct), i.e., the cycle when the amplification exceeds a
certain threshold above background fluorescence15,16. This allows detection of cells or organisms with
OnTEs caused by large deletions, large insertions or complex rearrangements (Fig. 1d). Performing
reliable qgPCR requires avoiding several pitfalls of ‘standard’ qPCR assays, which we explain in our
protocol. Following qgPCR, absence of LOH is confirmed by genotyping heterozygous SNPs around
the edited site. This step verifies that genomic regions that were heterozygous in the original unedited
cell line or organism are still heterozygous after editing. We provide two different options for this
analysis: nearby SNP genotyping and genome-wide SNP microarray analysis (Fig. 1e). Nearby SNP
genotyping determines zygosity of neighbouring SNPs by Sanger sequencing (Fig. 1f). We describe
how to identify, select and analyze suitable SNPs. For SNP microarray analysis we describe a detailed
workflow including selection of suitable chips, sample preparation and detailed instructions for data
analysis. We discuss advantages and disadvantages of both approaches and provide recommendations
and detailed descriptions for use depending on the edited locus and technological availabilities in
laboratories (see Box 1 for details).
Applications of the method
OnTEs are widespread in edited human iPSCs, other human cells and mice9–13, but probably also
occur in other organisms subjected to CRISPR editing. We have established our protocol using
CRISPR-edited human iPSCs. However, since complete analysis of OnTE is achievable using only
purified gDNA from the edited sample, this protocol can also be applied for detection in other edited
cell lines or animals (for discussion regarding application and limitations of the method in animals,
see below). Furthermore, the OnTE detection framework described in this protocol is applicable to
different types of introduced genomic changes: the main requirement for performing qgPCR is that
successful editing can be confirmed by a single genotyping PCR that spans across the edited site,
where we recommend a size not larger than 450 bp for efficient amplification of the PCR product.
Thus, OnTE evaluation by qgPCR is ideally suited for all cases in which either specific homozygous
single-base-pair changes were introduced by HDR-mediated editing, or small insertions–deletions
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(indels), as typically introduced by NHEJ-mediated editing to generate gene knockouts. If hetero-
zygous edits were introduced, the presence of both alleles can already be confirmed by Sanger
sequencing, making further analysis by qgPCR unnecessary. LOH analysis, however, should still be
performed (see below). Furthermore, larger genomic changes up to ~350 bp, such as targeted large
deletions/inversions or large knockins (e.g., for protein tagging) could also be checked for OnTEs as
long as the PCR spans the edit, although we have not tested this application. However, different
amplification efficiencies of the two differentially sized amplicons may complicate the analysis, and
therefore comparable PCR efficiencies should be ensured. Lastly, qgPCR may also be applied to edits
that are larger than the recommended 350 bp, such as fusion of GFP-tags to endogenous proteins.
However, this would require an amplicon specific to the edit, thus preventing normalization of the
qgPCR to the unedited ‘parent’ cell line or animal. In such a case, normalization to the reference assay
(e.g., at the telomerase reverse transcriptase (TERT) gene locus for human or transferrin receptor
(Tfrc) for mouse samples) could be performed, which also requires comparable qgPCR efficiencies to
determine defined copy numbers.
The LOH analysis is even more widely applicable and can be used to quality control all genome-
editing procedures without further adjustments, including those where large knockins were per-
formed. Furthermore, our methods for OnTE detection are in principle also applicable to non-
CRISPR genome editing tools, including ZFNs and TALEN. However, to our knowledge, it has not
been investigated yet whether cells or organisms edited with these tools are also affected by OnTEs.
Comparison with other methods
Several other methods have previously been used for OnTE detection.
Primer-walking is a PCR-based method that uses a series of primers with increasing distance to the
edited site to overcome the problem that closer primer binding sites are deleted by the OnTEs.
Although primer-walk PCRs in principle allow detection of large deletions at low cost, we have shown
recently that they are not always meaningful or reliable for detecting all OnTEs, especially in the
presence of large insertions or complex alterations that exceed the amplification limits of traditional
PCR13. Moreover, primer-walking PCR does not detect LOH.
Next-generation sequencing technologies allow the identification of OnTEs after editing at high
sensitivity and specificity10–12,17 by massively parallel sequencing of the area around the edited region
and analysis of read coverage and sequence. However, deep-sequencing-based methods are expensive,
Box 1 | Choosing nearby SNP genotyping or SNP microarrays for LOH analysis
Our protocol describes two options for detecting LOH after editing: nearby SNP genotyping and SNP microarrays. Both assays have distinct
advantages and disadvantages that every laboratory needs to consider. A decision as to which method should be used will be based on available
expertise, equipment and the desired information. Users requiring a maximal level of certainty may also consider performing both assays in
parallel.
Nearby SNP genotyping investigates editing-induced zygosity changes of nearby heterozygous SNPs by Sanger genotyping. This is a cheap and
simple assay that only requires identifying and genotyping heterozygous variants surrounding the target locus, and can therefore be easily
implemented with standard technologies available in most laboratories, such as Sanger sequencing. It is also more flexible than predefined SNP
microarrays because the genotyped SNPs can be freely chosen according to experimental needs. This custom design can improve detection of
small regions of LOH that may be missed by microarrays that might not assay affected SNPs close enough to the edited site. However, nearby SNP
sequencing only provides genotyping information for a restricted area and therefore further characterizing the extent of LOH events affecting large
parts of a chromosome is challenging. Another limitation of this method is that the zygosity of each SNP needs to be determined experimentally,
which can be laborious if editing was done in a region of low variation and no heterozygous SNPs are present directly near the edited site. If a
model cell line is used repeatedly in a laboratory for genome editing, it can be beneficial to obtain a whole-genome SNP profile using a high-density
SNP microarray once (see below), which can then guide selection of heterozygous SNPs for Sanger genotyping in subsequent experiments. Lastly,
SNP sequencing cannot be easily upscaled or automated, preventing efficient analysis of experiments with multiple edited loci or multiple
differentially edited lines.
SNP microarrays will investigate SNP zygosities and corresponding copy numbers on a genome-wide scale. A major advantage is that multiple cell
lines, in particular cell lines with different genome edits, can be analyzed in parallel in a timely manner. SNP microarrays are especially useful to
identify larger regions of LOH and to determine their full dimension. The reliability of SNP microarray data increases with the number of detected
SNPs in the affected area, and therefore small on-target zygosity changes of only one or a few SNPs can be challenging to resolve, depending on
the SNP coverage of the chip. This can be partially improved by choosing the most appropriate chip after investigating the SNP coverage of
different SNP microarrays at the target locus, and/or custom tailoring assayed SNPs, but even high-density chips will only cover a subset of SNPs
present in a cell line or organism. Lastly, LOH analysis by SNP microarrays is more expensive than nearby SNP genotyping, requires access to
suitable equipment and involves more complex data analysis.
It should be added that besides OnTE detection, microarray analysis can also be applied to investigate chromosomal aberrations genome wide by
‘molecular karyotyping’. This way, deletions or duplications larger than ~600 kb−1 Mb can be detected; however, smaller aberrations, and copy-
neutral inversions and balanced translocations, will be missed by microarray analysis.
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require specialized equipment and expertise for implementation, are only available to specialized
laboratories and require complex data analysis, especially for short-read-based sequencing methods
(producing reads of a few hundred base pairs): multiple ensemble algorithms for different types of
OnTEs need to be applied to map discordances between sample and reference genomes. However,
since OnTEs can include very diverse structural variations of the genome, the method may not detect
all OnTEs18,19. To overcome this problem, targeted long-read-sequencing approaches, e.g., from
Pacific Biosciences or Oxford Nanopore Technologies, can be applied. These will generate continuous
reads of several kilobases around the edited locus, which eliminates the need for complex read
assembly, but always restricts OnTE detection to the read length17,18.
Another alternative for OnTE detection could be droplet digital PCR, which is based on the
principle of a qPCR reaction, but additionally partitions the sample into thousands of individual
droplets (i.e., ‘reaction chambers’), allowing absolute quantification of target sequences12. This
increases sensitivity and specificity, but requires special equipment and more complex data analysis,
without—in our view—providing a major benefit for the purpose of OnTE detection.
Lastly, array-based technologies, such as comparative genomic hybridization (array-CGH) or SNP
microarrays, may be applied. Array-CGH is based on hybridization of sample and control gDNA and
is routinely used to perform molecular karyotyping with a resolution of up to 60 kb, which largely
surpasses standard G banding20. However, this resolution is still insufficient to detect many of the
OnTEs we detected in our iPSCs, which were in many cases well <10 kb (ref. 13). In addition, array-
CGH cannot reliably detect LOH. SNP microarrays are based on genome-wide SNP analysis by
hybridization of gDNA to oligo probes on a chip and provide information on SNP zygosity as well as
copy number. Although this method offers relatively high resolutions to also detect small LOH, it is
insufficient to also detect small deletions, small insertions or rearrangements affecting none, only one
or a few SNPs that we primarily found in our studies (see Box 1 for more details). Inversions or
balanced translocations at the edited locus will also be missed by SNP arrays.
Standard qPCR assays, without the design optimizations we implemented for qgPCR, are also
inadequate to detect OnTEs because they failed to reliably detect all affected clones (see qgPCR design
section for more details)13.
Experimental design
Detection of OnTEs after CRISPR editing consists of two main phases: (i) performing qgPCR to
confirm locus integrity and exclude the possibility of large deletions, large insertions or complex
rearrangements at the target locus; and (ii) investigate occurrence of LOH around the target site by
SNP genotyping, which can be performed either by nearby SNP genotyping and/or SNP microarrays
(see workflow in Fig. 2).
Timing of OnTE detection
Due to the frequent occurrence of OnTEs (up to 40% of HDR-edited human iPSCs13), we recom-
mend prioritizing their detection over other quality-control measures after CRISPR editing. In our
experiments exclusion of clones was more frequently due to OnTEs than other aberrations, such as
off-target effects, issues with pluripotency, integration of Cas9 plasmids, clonality or karyotype (Box 2
lists our general recommendations for quality controls after CRISPR editing in human iPSCs, other
cultured cells or animals). We therefore typically isolate gDNA of single-cell clones immediately after
editing and confirm successful editing by Sanger genotyping, directly followed by OnTE analysis.
For OnTE analysis, we recommend starting with qgPCR because OnTEs detected by this method,
such as large deletions, large insertions or complex rearrangements, seemed to occur more frequently
than LOH in human iPSCs. Furthermore, once optimized, qgPCR can easily be performed for
multiple samples in parallel in a few hours in a single qPCR reaction. Single-cell clones that do not
exhibit any abnormalities in the qgPCR assay are then further subjected to SNP genotyping, either by
nearby SNP sequencing or SNP microarray analysis, which takes ~2–3 d.
Controls
OnTEs are always detected by comparing gDNA from edited cells to that from unedited ‘parent’ cells
or organisms. As we occasionally observed variations in gDNA integrity from stored samples, we
recommend that control gDNA should be freshly isolated together with all other samples using a
method that provides high-purity gDNA. For qgPCR, the control sample serves as a normalization
factor to exclude clones that have acquired copy number changes by genome editing. For LOH
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analysis, the zygosity of different SNPs is first identified in the control sample. Then, using gDNA
from edited samples, the same SNPs are genotyped to ensure that heterozygous SNPs have main-













Identification of nearby heterozygous SNPs by
ensembl BioMart and validation in unedited cells
or organisms (Steps 22–27, 2–4 d)
Analysis of genomic DNA on genome-wide
SNP microarray (Steps 29–76, 3 d)
Select methods to exclude loss of heterozygosity (LOH, see Box 1):
SNP genotyping vs. SNP microarray (Step 21, 1 h)
Analysis of edited cells or organisms by qgPCR
to exclude those with OnTE (Steps 11–20, 1 d)
Design of labeled oligo for quantitative genotyping PCR (qgPCR)
(Steps 9 and 10, 1 h)
Identification of cells or organisms with desired edit by RFLP
and Sanger sequencing (Step 8, 2–3 d)
Design and optimization of 300–450 bp genotyping PCR
(Steps 3–7, 1 d)
Genomic DNA extraction (Step 2, 2 h)
CRISPR editing in cells or organism of interest (Step 1)
LOH analysis by SNP genotyping in edited cells or
organisms to exclude those with OnTE (Step 28, 1 d)
Processing of microarray data and analysis of log R
ratios and B allele frequencies to exclude cells or






















CRISPR-edited cells or organisms without detected OnTE
Fig. 2 | Overview of the procedure for simple and reliable OnTE detection after CRISPR genome editing. First, genome editing is performed in a cell
line or organism of interest (Step 1), followed by extraction of genomic DNA (Step 2). After design and optimization of a 300–450 bp genotyping PCR
(Steps 3–7), this PCR is used to identify cells or organisms with the desired edit by restriction fragment length polymorphism (RFLP) and Sanger
sequencing (Step 8). A labeled oligo for the quantitative genotyping PCR (qgPCR) reaction is then designed that matches the genotyping primers
(Steps 9 and 10). Next, edited cells or organisms are analyzed by qgPCR to exclude those with OnTEs like large deletions, large insertions or other
complex rearrangements (Steps 11–20). For the following LOH analysis, one of the two options should be selected: nearby SNP genotyping or SNP
microarray analysis (Step 21). For the first option, SNPs are identified by ensemble BioMart and validated in unedited cells or organisms (Steps 22–27).
The zygosity of heterozygous SNPs is then confirmed in edited cells or organisms to exclude those with OnTEs (Step 28). For the second option,
genomic DNA is first analyzed on a genome-wide SNP microarray (Steps 29–76), followed by processing of log R ratios and B allele frequencies to
exclude cells or organisms with OnTEs (Steps 77–91).
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qgPCR design
Performing qgPCR requires applying a qPCR assay amplifying a region of ~300–450 bp spanning across
the edited genomic locus. The qgPCR assay consists of two primers amplifying the target region and a
fluorescently labeled probe that allows quantification of the PCR reaction. We recommend reusing
primers that were previously designed for genotyping the locus by Sanger sequencing and combining
them with a matching probe using a qPCR design tool that allows probe design for existing primer
sequences. The probe is then ordered as a custom oligo using dye and quencher fitting to local qPCR
infrastructures. In the qPCR reaction, a copy number reference assay should be run together with the
qgPCR assay for the edited gene. Amplifying a reference gene known to be present in two copies in the
genome enables the gene of interest to be normalized to an endogenous control. Thus, Ct value differences
caused by different amounts of gDNA in the reaction tube can be normalized.
When we developed the method in our original study, we investigated the possibility of assay artefacts
by testing two different qgPCR assays with primers being shifted in different directions relative to the cut
site as well as probes positioned on different sides of the cut site at three different loci in human iPSCs13.
In these experiments, we did not observe conflicting results between different assay sets and therefore
conclude that one qgPCR is sufficient for reliable OnTE detection. However, users requiring a maximal
level of certainty may still consider using two or more independent assays based on our design principles.
Commonly used design tools for quantitative PCR (qPCR) typically recommend amplicon sizes of
no more than 150 bp for qPCR assays. But, as we have shown recently13, this size is not sufficient for
reliable on-target analysis after genome editing. In several cases the assays failed to reliably flag clones
affected by OnTEs where insertions or deletions did not directly overlap with the cut site. This
allowed primers from the short amplicon assay to still bind and amplify the aberrant allele, leading to
false-negative signals in the qgPCR. Longer amplicons with the recommended length of 300–450 bp
were sufficient to reveal OnTEs non-contiguous with the cut site. Therefore, this size is a good
Box 2 | Overview of quality controls after CRISPR editing in iPSCs, other cultured cells or animals
CRISPR editing can lead to a variety of non-intended alterations in the genome. These can be induced by the CRISPR-associated nuclease around
the edited site (OnTEs) or in other regions of the genome (off-target effects). Additionally, the process of editing and cultivation of single cells
subjects cells to stress and can induce or enrich chromosomal aberrations. To allow meaningful comparisons between edited cells or organisms
and their non-edited isogenic controls, non-intended alterations need to be excluded as much as this is technically possible. We apply a quality
control workflow for each edited iPSC line35 and founder animal, which is prioritized according to frequency of occurrence as well as the cost and
complexity of the assay:
1 OnTEs (cells and animals): as described in this protocol, every line or founder is screened for OnTEs by qgPCR and SNP genotyping (see
discussion above about applicability in animals).
2 Chromosomal aberrations (cells and animals): both cutting a chromosome by CRISPR and single-cell cloning can induce chromosomal
aberrations, such as translocations, trisomies, deletions or inversions. Such alterations can be detected by karyotyping, using traditional G
banding, or SNP microarray-based molecular karyotyping (see Box 1). Molecular karyotyping is more affordable and provides higher-resolution
data but cannot detect balanced translocations and inversions. As both assays are still relatively expensive, we recommend prescreening for the
most typical aberration by qPCR36. In our human iPSCs this is a local trisomy of Chr 20q11.21 (BCL2L1), but qPCR detection of other
aneuploidies can be added, depending on expected occurrence in the edited cell line or organism.
3 Off-target effects (cells and animals): guide RNAs with low predicted off-target rates are chosen using CRISPOR37. After editing, potential off-
target effects are determined by Sanger sequencing the top five off-target hits from both MIT and CFD scoring algorithms38–40. Off-target
detection can also be performed by more unbiased methods such as DISCOVER-seq, Guide-Seq or whole-genome sequencing5,7,8. In animals,
backcrossing is usually applied to remove non-linked off-target effects. Another possibility to exclude negative consequences of off-target
effects is to work with two lines edited by different gRNAs with non-overlapping off-target profiles.
4 Identity of cell line or animals: fingerprinting of cell lines can be applied to exclude mix-up during editing or contaminations with different cell
lines. Lines can be fingerprinted thoroughly by STR profiling35, but if a laboratory only uses a limited number of lines, a simple PCR assaying one
variable genomic locus can be sufficient to distinguish lines from several iPSC donors. We assay a microvariation at the human D1S80 locus on
Chromosome 1 (ref. 41). Variability of alleles between individuals can be visualized by analyzing PCR products on a 2% (wt/vol) agarose gel
(PCR described in step 4: annealing temperature, 68 °C; extension time, 1 min; primers, GTCTTGTTGGAGATGCACGTGCCCCTTGC,
GAAACTGGCCTCCAAACACTGCCCGCCG). In animals, genetic background can be determined. If untreated or littermate controls are
unavailable, and the exact genetic background is unknown, identification of the correct strain can be easily achieved using genetic strain panels
from commercial providers (e.g., Genome Scanning Service, JAX). Alternatively, known variations between different (sub)strains (such as the
Nnt deletion or Crb1rd8 mutation in mice42–44) can be analyzed by PCR-based assays to identify the actual genetic background.
5 Mixed cell population (cells only): we check clonality of edited iPSC lines by plating edited clones as single cells on a 10 cm dish, followed by
picking and genotyping 30–50 clones as described in ref. 27.
6 Genomic integration of editing components (cells and animals): if plasmids were used for editing, their genomic integration needs to be
excluded, e.g., by PCR and/or absence of antibiotic resistance mediated by the plasmid. If exclusion of HDR repair template off-target
integration is desired (integration is less likely when using ssODNs, instead of double-stranded donors), qgPCR could be redesigned to
determine repair template copy numbers within the genome. For this, both primers and probe would have to lie within the repair template.
7 Pluripotency (stem cells only): as CRISPR editing of an iPSC line usually does not affect its pluripotency, it is sufficient to confirm typical stem
cell morphology by live brightfield microscopy and the presence of pluripotency factors (e.g., Oct4, Tra1-60, SSEA4, Nanog)28 by
immunofluorescence staining. To further confirm pluripotency, scorecard assays or in vitro undirected embryoid-body-based differentiation
followed by identification of expression markers for all three germ layers can also be performed45.
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compromise between efficiency of qPCR (which decreases with increasing amplicon length) and
likelihood of OnTEs (which decreases with increasing distance from the cut site).
LOH analysis by SNP genotyping
We applied and validated two methods for LOH analysis: nearby SNP sequencing and SNP microarrays.
Both assays provide genotype information that can be applied to exclude the occurrence of LOH around
the edited locus. It is up to the user to decide which assay is more appropriate for individual experiments
and laboratory requirements (see detailed discussion of benefits and challenges in Box 1).
Nearby SNP sequencing. Performing nearby SNP sequencing for LOH analysis requires first
identifying potentially heterozygous SNPs on both sides of the edited locus in the ‘parent’ cell line or
organism using Ensembl BioMart21, followed by validation of heterozygosity using Sanger sequen-
cing. BioMart accesses the Ensembl databases with genomic variants that can be filtered by, e.g.,
genomic region, type of variants and allele frequency. We recommend first concentrating on a region
of ~10 kb around the edited site and human short variants with a global minor allele frequency
(MAF) ≥0.3. If these settings do not allow retrieval of ~5–10 SNPs on each side, the genomic region
can be increased or the cutoff for MAF decreased. The flanking sequence around the variants is
downloaded from Ensembl and used as a basis for genotyping SNPs by PCR and Sanger sequencing.
To exclude the occurrence of LOH, it is necessary to identify one heterozygous SNP on each side of
the targeted locus in the unedited cell line or organism to allow thorough analysis after editing.
Assuming independent inheritance of the SNPs (no linkage disequilibrium), a maximum of nine
SNPs with an MAF ≥0.3 have to be checked to reach a 99% chance of finding a heterozygous one
(allele frequency according to Hardy–Weinberg = 2 × 0.7 × 0.3 = 42%, minimum probability n = ln
(1 − 0.99)/ln(1 − 0.42) = 8.5). If desired, nearby SNP genotyping can be extended to loci further
away from the cut site to determine the dimension of large regions of LOH.
SNP microarray. For analysis by SNP microarrays it is important to select chips with sufficient
SNP coverage in the edited region. Several biallelic variants should be assayed near the targeted site
(preferably within 10–50 kb) on each side of the targeted locus. Only the SNPs that are heterozygous
in the unedited ‘parent’ cell line/organism will be informative for LOH analysis, and their availability
will vary depending on genomic region and the cell line/organism to be assayed. Chips assaying more
SNPs around the locus will yield more reliable data, and assaying closer to the target site will allow
detection of smaller regions of LOH. SNP microarrays can also be customized to a certain degree,
which allows more SNPs in a region of interest to be assayed. We applied the Illumina Global
Screening Array v.2 genotyping chip, which is an affordable option commonly used for genome-wide
association studies22 and has a reasonably dense and well-balanced genome-wide coverage (one SNP
every 4.4 kb). Other higher-density chips by Illumina or other manufacturers, such as Infinium
Omni2.5-8 or UK Biobank Axiom Array (Thermo Fisher Scientific), and so on, can likewise be used
to further increase SNP coverage.
Most SNP arrays are designed for high-throughput genotyping—for instance, the Illumina Global
Screening array processes 24 samples on one chip—and therefore it is most cost effective to analyze
multiple samples in parallel. In addition, specific equipment is needed for chip analysis which makes
LOH analysis by SNP microarray more expensive than nearby SNP sequencing. For these reasons,
SNP chip genotyping is often outsourced to companies or core facilities. Analysis of raw chip data is
performed using GenomeStudio software from Illumina, which is downloaded together with chip-
specific manifest and cluster files from the manufacturer’s website.
Expertise needed to implement the protocol
All steps of our protocol are optimized wherever possible for maximal accessibility and modest requirements
for specialized infrastructure, and can be performed with the expertise and equipment typically available in a
laboratory performing CRISPR genome editing. This includes performing and optimizing PCR, qPCR and
Sanger sequencing, the latter typically being outsourced to a company or core facility. The same technologies
are required to perform SNP genotyping. If LOH analysis is performed using SNP microarrays, access to
specific equipment, such as pipetting robots, hybridization ovens and an iScan scanner, is required, but this
can also be outsourced to a core facility or commercial provider.
Limitations
A limitation of our technology is that qgPCR relies on PCR amplification of the edited locus, which
may not work for some loci due to local sequence composition, e.g., very high GC content or
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repetitive sequences. However, if the edited locus is not compatible with PCR, verification of suc-
cessful editing by Sanger sequencing would also be prevented, thus causing a general obstacle to
validating CRISPR editing. Furthermore, qgPCR is not an optimal OnTE detection method if very
large edits are desired, such as kilobase-sized insertions, because the PCR could not span the entire
edit with primers in the flanking genomic regions. As discussed above, careful redesign and validation
for PCR efficiencies may still allow adapting qgPCR to such a scenario.
Another potential limit of our assays is that they will not identify chromosomal alterations that occur
not directly at the target site and therefore do not affect the amplicon of the qgPCR but are also too small
to be detected by SNP sequencing or microarrays. For example, translocation of a small region containing
the entire qgPCR amplicon to another genomic position or large inversions would not affect copy number
values of qgPCR and zygosities in SNP microarrays. However, as the genomic cut by Cas9 is the initial
trigger for the formation of OnTEs, we expect that the large majority of OnTEs will affect the immediate
region around the target site, and therefore events escaping detection would be extremely rare.
qgPCR and SNP genotyping is a crucial quality-control measure to increase reliability of CRISPR-
based studies by excluding edited cells and organisms with OnTEs. However, it is important to keep
in mind that although our tools are useful to exclude OnTEs, other editing-induced issues such as off-
target effects can still be present in the edited cell or organism and therefore should also be inves-
tigated carefully (see Box 2).
Application and limitations of the method in animals
Although we have tested our OnTE detection technology only in human iPSCs, its general principles
also allow OnTE detection to be performed in edited animals. However, its full applicability and
usefulness depends on several factors that differ between edited cells and animals, necessitating
careful consideration.
First, our protocol requires clonality of analyzed organisms, which is often not achieved in edited
animals. The F0 generation of many model organisms may be mosaic after genome editing due to
editing in multicellular stages and/or multiple parallel editing events. Assaying mosaic samples with a
mixture of different genomes is complex and requires more sophisticated methods than qgPCR/bulk
SNP genotyping, such as targeted deep sequencing. For this reason, prevention of unwanted OnTEs is
currently mainly performed by backcrossing of edited animals, which separates alleles with OnTEs
from correctly edited alleles. However, genome-editing protocols are constantly becoming more
versatile, and there is increasing interest in using edited animals already in the F0 generation (i.e., the
animal edited as an embryo/zygote is directly assayed) to generate more rapid experimental results. It
has been shown that mosaicism can be reduced by performing editing in one-cell-stage embryos with
CRISPR ribonucleoproteins (RNPs) instead of plasmids or RNA23 or by accelerated proteasomal
degradation of Cas9 (ref. 24). Li et al.25 recently reported a dramatic decrease in genetic mosaicism by
spatiotemporal control of Cas9 activity in mouse embryos, leading to the generation of identical
biallelic F0 mutants. As a proof of concept, especially for species with long generation lengths and/or
costly husbandry, they achieved high frequency of identical biallelic editing with little mosaicism. It is
therefore conceivable that further improvements in editing and preimplantation technologies will
lead to wider use of edited animals directly in the F0 generation, making our OnTE detection protocol
a useful addition to quality-control measures.
Second, testing for LOH is only relevant in cell lines and animals with a variable genetic back-
ground. Whereas most human cell lines bear the genetic variability of their donors, inbred animals
and cell lines derived from them, which are often used as model organisms in laboratories, are
considered to be genetically identical and homozygous at every SNP (apart from spontaneous
mutations). Therefore, LOH cannot occur, which makes testing for it unnecessary. However, if
genetically variable outbred animals (such as many common rat models or diversity outbred mice26,
which mimic human genetic diversity) are used, our technology can be applied to exclude LOH after
genome editing, regardless of the species.
Materials
Biological materials
! CAUTION For work with iPSCs informed consent must be obtained from the respective subjects.
Studies with iPSCs or animals must conform to all relevant institutional and governmental regulations.
! CAUTION Cell lines should be routinely checked for authenticity and contamination with mycoplasma.
● Female iPSC line A18944 (ThermoFisher Scientific, cat. no. A18945; RRID: CVCL_RM92)
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Reagents
Genomic DNA extraction
● PBS (Sigma, cat. no. D8537)
● Ethanol absolute (VWR, cat. no. 20821.310)
● NucleoSpin Tissue Kit (Machery-Nagel, cat. no. 740952.50)
PCR and gel electrophoresis
● Custom primers designed to amplify a 300–450 bp region around the edited locus (IDT, see
Supplementary Table 1 for primer sequences used in our experiments)
● OneTaq Quick-Load 2× Master Mix with standard Buffer (NEB, cat. no. M0486S)
● UltraPure, DNase/RNase-Free Distilled Water (Invitrogen, cat. no. 10977-035)
● Agarose SERVA Wide Range (SERVA, cat. no. 11406.01)
● TAE buffer, 50× (Thermo Fisher Scientific, cat. no. B49)
● SYBR Safe DNA Gel Stain (Invitrogen, cat. no. S33102) ! CAUTION SYBR Safe has possible mutagenic
affects. Wear full personal protective equipment (PPE) and handle with care in a designated separate
working area.
● Gene ruler 100 bp plus DNA ladder (Thermo Fisher Scientific, cat. no. SM0323)
qgPCR
● PrimeTime Gene Expression Master Mix (IDT, cat. no. 1055770)
● Human TaqMan Copy Number Reference Assays (human TERT on chromosome 5, Thermo Fisher
Scientific, cat. no. 4403316, or human RNase P on chromosome 14, Thermo Fisher Scientific, cat. no.
4403326) c CRITICAL Reference gene assays should target a locus on a different chromosome than the
edited locus to exclude problems due to large chromosomal aberrations on the edited chromosome.
● Mouse TaqMan Copy Number Reference Assays (mouse Tfrc on chromosome 16, Thermo Fisher
Scientific, cat. no. 4458366, or mouse Tert on chromosome 13, Thermo Fisher Scientific, cat. no.
4458368) c CRITICAL Reference gene assays should target a locus on a different chromosome than the
edited locus to exclude problems due to large chromosomal aberrations on the edited chromosome.
● Fluorescently labeled probe for target-specific qgPCR (see Supplementary Table 1 for probe sequences
used in our experiments), e.g., designed using the IDT PrimerQuest tool and ordered from IDT as
PrimeTime Eco Probes 5′ 6-FAM/ZEN 3′ IBFQ (FAM label on the 5′ end and a double-quencher with
ZEN/Iowa Black FQ at the 3′ end). The ‘Eco’ scale of 2.5 nmol is sufficient for a maximum of
668 single qgPCR reactions as described in step 12 c CRITICAL The design of the probe must not
overlap with the cut site or intended mutation; see Procedure for details.
Nearby SNP sequencing
● Custom PCR primers amplifying a 300–500 bp region flanking SNPs derived from BioMart (IDT,
see Supplementary Table 1 for primer sequences used in our experiments)
SNP microarray
● Infinium Global Screening Array-24+ v.2 Kit (48 samples, Illumina, cat. no. 20030773)
● NaOH, 0.1 M (Merck, cat. no. 43617) ! CAUTION NaOH is highly corrosive when concentrated. Wear
appropriate PPE and work in a chemical fume hood.
● 2-Propanol (Merck, cat. no. I9516)
● Formamide (Carl Roth, cat. no. 6749.1) ! CAUTION Formamide is toxic; use under a fume hood and
wear full PPE.
● EDTA, 500 mM (Merck, cat. no. 20-158)
Equipment
General laboratory consumables
● PCR plate, 96 well, semi-skirted (BRAND, cat. no. 781374) c CRITICAL For qgPCR, use plates that fit
the qPCR machine (as recommended by the manufacturer).
● LightCycler 480 Sealing Foil (Roche, cat. no. 04729757001)
● NucleoSpin Gel and PCR clean-up kit (Machery-Nagel, cat. no. 740609.50)
● 8-Strip PCR tubes with domed lids (Biozym, cat. no. 711047)
● Standard 1.5 ml centrifuge tubes (Eppendorf, cat. no. 0030 120.086)
● Standard 2.0 ml centrifuge tubes (Eppendorf, cat. no. 0030 120.094)
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● Sterile pipette tips with filters, 2.5 µl (Sarstedt, cat. no. 70.1130.212)
● Sterile pipette tips with filters, 200 µl (Sarstedt, cat. no. 70.760.211)
● Sterile pipette tips with filters, 1,250 µl, long (Sarstedt, cat. no. 70.1186.210)
● Storage plate, 0.8 ml (MIDI plate), conical well-bottom (Abgene, cat. no. AB-0765)
● 96-Well cap mats (Abgene, cat. no. AB-0566) c CRITICAL Ensure that plates and cap mats fit heating
blocks and pipetting robots.
● Heat sealing foil (Abgene, cat. no. 0559)
● Tape Pads adhesive foil (Qiagen, cat. no. 19570)
● Cell lifter (Corning, cat. no. CLS3008)
● Qubit Assay Tubes (Thermo Fisher Scientific, cat. no. Q32856)
● Qubit dsDNA BR Assay Kit (Thermo Fisher Scientific, cat. no. Q32850)
General laboratory equipment
● ProFlex 96-well PCR System (Applied Biosystems, cat. no. 4484075)
● Microcentrifuge (Eppendorf, cat. no. 5417R)
● PeqPOWER 300 V power supply (Peqlab, cat. no. 55-E300-230V)
● Horizontal gel electrophoresis chamber (Peqlab, cat. no. 40-1214)
● ThermoMixer C (Eppendorf, cat. no. 5382000023) and Thermoblock (Eppendorf, cat. no. 5361000031)
● Gel imaging system (Bio-Rad, cat. no. 1708265)
● Pipette, 0.1–2.5 µl (Eppendorf, cat. no. 3120000011)
● Pipette, 2–20 µl (Eppendorf, cat. no. 3120000038)
● Pipette, 20–200 µl (Eppendorf, cat. no. 3121000082)
● Pipette, 100–1,000 µl (Eppendorf, cat. no. 3121000120)
● StepOnePlus Real-Time PCR System (Thermo Fisher Scientific, cat. no. 4376600)
● NanoDrop 2000c Spectrophotometer (Thermo Fisher Scientific, cat. no. ND-2000C)
● Qubit 4 Fluorometer (Thermo Fisher Scientific, cat. no. Q33238)
Processing of Illumina chips
● Tecan eight-tip robot (Illumina, cat. no. SC-30-402)
● Infinium HD Starter Kit (24 beadchip) 220V (Illumina, cat. no. 20028879)
● iScan scanner with software (Illumina, cat. no. SY-101-1001, https://emea.illumina.com/systems/array-sca
nners/iscan.html, user guide: https://support.illumina.com/content/dam/illumina-support/documents/
documentation/system_documentation/iscan/iscan-system-guide-11313539-01.pdf)
● Cooling microplate centrifuge with adapters for 0.8 ml MIDI plates and tubes (Sigma, cat. no. 4K15C)
Software
● SnapGene Viewer v.4.3.10 (SnapGene, https://www.snapgene.com/snapgene-viewer/)
● Illumina Decode File Client (Illumina, https://emea.support.illumina.com/array/array_software/
decode_file_client/downloads.html)
● GenomeStudio v.2.0.5 with genotyping module v.2.0.5. (Illumina, https://emea.illumina.com/
techniques/microarrays/array-data-analysis-experimental-design/genomestudio.html)
● iScan Control software v.4.0.0 (Illumina, https://emea.support.illumina.com/downloads/iscan-control-
software-release-notes.html)
Reagent setup
Preparation of qgPCR probe
Briefly centrifuge the tube at 500g for 10 s at room temperature and resuspend in TE buffer pH 8.0 to
a final concentration of 15 µM. Probe is light sensitive and should always be stored in dark conditions
at −20 °C, where it is stable for up to 2 years.
Preparation of qgPCR assay
Mix assay components to a final concentration of 10 µM (each primer) and 5 µM (probe). Prepare
30 µl aliquots and store reconstituted assay in dark conditions at −20 °C, where it is stable for up
to 2 years.
TAE buffer solution for electrophoresis
Dilute 50× TAE buffer to a 1× working solution using deionized water.
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Agarose gels for electrophoresis
Prepare 2% (wt/vol) agarose solution in 1× TAE buffer. Microwave solution in a shatterproof
glass container without the lid until agarose has dissolved. Add 10,000× SybrSafe and pour
the liquid into a gel chamber with the desired combs. Gels can be used when solid or stored
at 4 °C for 1 week.
Procedure
CRISPR editing in cells or organism of interest ● Timing 1–3 months, depending on cell
type and organism
1 Perform genome editing in cells or organisms of interest according to published efficient
CRISPR protocols (e.g., refs. 27–31). Briefly, this includes designing a suitable guide RNA (gRNA)
for the targeted locus and expressing the guide RNA together with WT Cas9, a Cas9 variant or a
related other Cas nuclease in the cell line or organism to be edited, either by plasmid, mRNA or
as RNP.
gDNA extraction ● Timing 2 h
c CRITICAL Subsequent steps require high-quality gDNA. Crude DNA extracts from rapid protocols
lacking proteinase K digest will not work reliably.
c CRITICAL Stored gDNA samples often show varying integrities, which is problematic for the
following qgPCR. We therefore recommend simultaneous harvesting and gDNA extraction of all
samples, including controls (see step 11).
2 Harvest cells for gDNA extraction. For edited single-cell clones, follow option A; for tissues of edited
mice or other organisms, follow option B.
(A) Harvest and gDNA extraction of edited single-cell clones
(i) After genome editing, expand single-cell clones in tissue culture to obtain
500,000–1,000,000 cells for gDNA extraction. Wash attached cells once with PBS without
dislodging them from the plate, aspirate and add 1 ml of fresh PBS for harvesting.
Simultaneously harvest unedited control sample for gDNA extraction.
(ii) Scrape cells off the plate using a cell lifter and triturate to remove clumps; transfer the cells
to a 1.5 ml Eppendorf tube.
(iii) Pellet cells by centrifugation at 1,000g for 2 min at room temperature (20–25 °C). Aspirate
PBS and place cell pellets on ice.
j PAUSE POINT Cell pellets can also be stored at −80 °C for up to 1 year.
(iv) Extract gDNA from each sample, including controls, using a gDNA extraction kit, such as
NucleoSpin Tissue (Macherey-Nagel), according to the manufacturer’s instructions.
(B) Harvest and gDNA extraction of edited organisms
(i) Collect animal tissue (e.g., 5 mm of mouse tail, 10–25 mg of organ or ear/tail clip biopsy).
c CRITICAL STEP Fresh tissue should be processed as soon as possible to prevent
degradation of gDNA. Until then, store tissue at −20 or −80 °C.
(ii) Extract gDNA from each sample, including controls, using a gDNA extraction kit, such as
NucleoSpin Tissue (Macherey-Nagel), according to manufacturer’s instructions.
Design and optimization of 300–450 bp genotyping PCR ● Timing 1 d
c CRITICAL All genotyping and qgPCR reactions require an optimal PCR product without additional
bands or low product yield. This is achieved by selecting an optimal primer pair from several primer
candidates as well as optimizing yield and annealing temperature using gradient PCR.
3 Locate edited locus, e.g., by BLASTing guide RNA sequences, and export ~300 bp on each side of
the target locus from Ensembl (http://www.ensembl.org) or another genome browser. Paste the
sequence into a primer design tool, such as Primer3Plus (https://primer3plus.com/), and use default
settings to select primers. The intended PCR product should amplify a 300–450 bp region with the
target locus placed near the middle (distance between primer and target site should be at least 100
bp). Order three different forward and reverse primers.
c CRITICAL STEP In case of HDR-mediated editing, ensure that at least one primer lies outside of
the repair template to avoid misleading results in the following qgPCR reaction due to residual
template still being present in the cells after editing.
4 Prepare the following PCR reaction using the primers to amplify the target locus from gDNA of the
unedited ‘parent’ cells or organism. We recommend testing all nine possible primer combinations
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at different annealing temperatures (see next step). For this, prepare a master mix for each
combination with individual 10 μl PCR reactions.
Components Amount Final concentration
Genomic DNA 10 ng 1 ng/μl
2× OneTaq Quick-Load Master Mix 5 μl 1×
Forward primer (10 μM) 0.2 μl 0.2 μM
Reverse primer (10 μM) 0.2 μl 0.2 μM
DNase-free H2O To 10 μl —
5 Run a gradient PCR using the following thermocycler program with annealing temperatures
varying between 50 and 70 °C in 4 °C steps (six temperatures for each combination).
c CRITICAL STEP NEB recommends an extension temperature of 68 °C for OneTaq Master mix. If
a different polymerase enzyme or master mix is used for the PCR reaction, thermocycling
conditions might need to be adjusted according to manufacturer‘s instructions.
Step Temperature (°C) Time Number of cycles
1. Initial denaturation 94 5 min 1×
2. Denaturation 94 30 s 35×
3. Annealing 50–70 30 s
4. Extension 68 30 s
5. Final extension 68 5 min 1×
6. Hold 10 Until ready to process 1×
6 Analyze PCR products by agarose gel electrophoresis. Load 5–10 μl of each sample together with
DNA ladder on a 2% (wt/vol) agarose gel with SYBR Safe (1×). Run gel at 150 V to separate DNA
bands until the loading dye front migrates through ~75% of the gel. Visualize bands using an
appropriate gel imager. Determine the best temperature and primer combination that yields a
single, strong PCR product.
? TROUBLESHOOTING
7 Scale up all reagents to a total volume of 50 μl and repeat the reaction for the best PCR product.
Purify the reaction using a PCR clean-up kit, such as NucleoSpin Gel and PCR Clean-Up
(Macherey-Nagel). Sanger sequence the product to confirm that it matches the sequence obtained
from the genome browser.
c CRITICAL STEP Genomic sequence of target cells may differ from genome databases because of
SNPs or database errors. Always confirm that the correct sequence is used for designing all
genome-editing and quality-control reagents.
? TROUBLESHOOTING
Identification of cells or organisms with desired edit by restriction fragment length
polymorphism and Sanger sequencing ● Timing 2–3 d
8 Identify clones or organisms with desired edit by amplifying the edited region with the above-
optimized PCR, analyzing PCR products by gel electrophoresis and Sanger sequencing. If a large
number of clones or founder animals needs to be screened and the edit introduces a restriction
enzyme site, a restriction fragment length polymorphism assay (as described, e.g., in refs. 27,28) can
also be used for screening of positive samples.
c CRITICAL STEP It is important to analyze genotyping PCR products by agarose gel
electrophoresis before Sanger sequencing. This will help to exclude clones with small deletions
or insertions that occurred within the genotyping amplicon, which will lead to double bands or
size-shifted bands on a gel.
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Design of labeled oligo for qgPCR ● Timing 1 h
9 Enter the genomic sequence surrounding the target locus into a qPCR design tool, such as IDT
PrimerQuest. Enter the available primer sequences from the optimized genotyping PCR (Step 6)
under ‘partial design input’ and leave default settings for other parameters.
c CRITICAL STEP To avoid overlap with edited bases that would affect the assay, enter the edited
site as an excluded region for the probe. If NHEJ-edited cells or organisms need to be analyzed,
exclude 5–20 bp on each side of the cut site, depending on the maximal size of indels that
are desired.
c CRITICAL STEP Default design parameters and outcomes for qPCR probes and corresponding
primers can vary for other design tools, such as Primer3Plus or Primer-BLAST. We therefore
recommend checking amplification curves of the qPCR reactions (Step 16) and single bands by
agarose gel electrophoresis (Step 19).
10 Order fluorescently labeled probes for target-specific qgPCR with modifications fitting the
specifications of your qPCR machine.
c CRITICAL STEP The copy number reference assays we suggest (e.g., TERT for humans and
Tfrc for mice) are labeled with VIC dyes. To enable duplex qPCR reactions (i.e., two targets
are amplified in a single well) to be performed, it is necessary that probes for the gene of interest
and reference gene are labeled with two different colors. Compatibility of colors with the
qPCR machine needs to be checked individually, but typically, a FAM-dye-labeled probe is used
together with a VIC-dye-labeled probe. In both cases, a quencher molecule on the probe
prevents the dye from emitting a signal until it is cleaved off and hence activated by the
polymerase’s exonuclease activity.
Analysis of edited cells or organisms by qgPCR to exclude those with OnTEs ● Timing 1 d
c CRITICAL Avoid contamination of your samples and reagents with foreign nucleic acids by using
filter tips for pipetting throughout the qPCR experiment. We also recommend using a dedicated space
and pipettes and, if available, a ultraviolet-treated clean hood for pipetting the qgPCR.
c CRITICAL Include one unedited control gDNA sample and one no-template (only water) control. If
edited cell lines/organisms from previous editing rounds have already been characterized by qgPCR and
yielded samples with only one allele at the same targeted locus, fresh gDNA from these samples can be
added as an additional positive control.
11 Determine DNA concentration of gDNA samples using a spectrophotometer. Prepare 9.5 μl of a 10
ng/μl dilution of gDNA with DNase-free H2O for triplicate reactions (see step 12) in a new
microcentrifuge tube (or 6.5 μl for duplicate reactions).
c CRITICAL STEP Accurate determination of sample concentration is important for the subsequent
qPCR reaction. A spectrophotometer is usually sufficient, but if desired a more precise
measurement using a Qubit fluorometer can be performed.
12 Prepare the following qgPCR reaction master mix. Check the PrimeTime Gene Expression Master
Mix instructions or the manual of your qPCR machine if a reference dye needs to be added. Thaw
all components on ice and prepare a master mix for all samples without gDNA. Briefly vortex to
mix all reagents thoroughly. We recommend running each sample in triplicate. Volumes provided
are for one reaction in one well; scale up all components as necessary and add ~10% extra volume
to account for small pipetting errors.
Components Amount (μl) Final concentration
2× PrimeTime Gene Expression Master Mix 7.5 1×
20× qgPCR assay (see ‘Reagent setup’ section) 0.75 1×
20× TaqMan Copy Number Reference Assay 0.75 1×
DNase-free H2O 3 —
c CRITICAL STEP Analyzing samples in three technical replicates is helpful to identify outliers. For
more experienced users of qPCR experiments, it might be sufficient to analyze samples in duplicate
to save material cost.
13 For triplicate reactions, add 38 μl of qgPCR reaction master mix (or 26 μl for duplicate reactions)
from step 12 to each sample from step 11.
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14 Pipette 15 μl of qgPCR reaction mix from the previous step into each well. Seal the plate with
optically transparent film suitable for qPCR reactions. Avoid fingerprints or other marks on the
film. Centrifuge the plate at 1,000g for 1 min at 4 °C.
c CRITICAL STEP To decrease technical variability in your qPCR reaction resulting from different
amounts of reagents in each well, it is extremely important to focus on a consistent pipetting technique.
j PAUSE POINT The prepared qPCR plate can be stored in dark conditions at 4 °C for a few hours.
Briefly vortex and centrifuge before continuing with the next step.
15 Run qgPCR reaction on a qPCR thermocycler using the following program.
Step Temperature (°C) Time Number of cycles
1. Polymerase activation 95 5 min 1×
2. Denaturation 95 15 s 40×
3. Annealing/extension 60 1 min
4. Hold 10 Until ready to process 1×
16 Examine the amplification plot of qPCR reactions. It should show a baseline at the beginning, a
logarithmic amplification phase (this phase is usually within qgPCR reaction cycles 20 to 30 and
includes the Ct value; see Fig. 3c,d) and a plateau toward the end of the run. Discard samples with
abnormal amplification plots from the analysis. Detailed discussion on baselines and amplification
plots can be found elsewhere16.
17 Analyze Ct values of samples. Obtain Ct values from qPCR machine software using auto baseline
settings and export values to an Excel file. Calculate mean Ct values from technical replicates and
standard deviation. The ‘no template control’ should not show any target amplification and the
standard deviation should not be >0.2.
From our experience, Ct values of qgPCR assays for target genes may vary but are usually
~25–26. Ct values for TERT are usually between 27 and 28. Variations can be caused by different
amounts of gDNA between wells or different efficiencies of PCR reactions. Low amplicon levels will
result in high Ct values with a greater chance of high variation between samples. Therefore, a Ct
value threshold of 30 may be used to prevent unreliable results32.
? TROUBLESHOOTING
18 For relative quantification calculate ΔΔCt by normalizing target gene values to the internal reference
gene and unedited control sample using the following equation (with mean Ct values for each):
ΔΔCt ¼ Ct meantarget  Ct meanreference
 
edited sample
 Ct meantarget  Ct meanreference
 
unedited control
To get the fold difference, calculate 2−ΔΔCt. Multiply values by 2 to get the total number of alleles.
Edited samples should either have two alleles (i.e., no OnTEs) or one allele (i.e., OnTEs detected).
? TROUBLESHOOTING
19 Analyze qgPCR products by agarose gel electrophoresis. Load one entire 15 μl reaction together
with 2 μl DNA ladder on a 2% (wt/vol) agarose gel with SYBR Safe (10,000×). Run gel at 150 V to
separate DNA bands until the loading dye front migrates through ~75% of the gel. Visualize bands
using an appropriate gel imager.
c CRITICAL STEP All analyzed samples should have one single band from target locus amplification
and one band from the reference assay (e.g., human TERT at 88 bp or mouse Tfrc at 91 bp).
? TROUBLESHOOTING
20 Edited single-cell clones/animals with two alleles in the qgPCR reaction and one single PCR
product on the agarose gel do not contain OnTEs such as large deletions, large insertions or other
complex rearrangements. Exclude all other clones or animals.
Select methods to exclude LOH ● Timing 1 h
21 After qgPCR, edited single-cell clones or organisms should be subjected to LOH analysis. For this
purpose, we describe two distinct options in the following protocol: nearby SNP genotyping and
SNP microarrays. If unsure which one to select, consider our discussion of the advantages and
disadvantages in Box 1 or perform both assays in parallel.
NATURE PROTOCOLS PROTOCOL
NATURE PROTOCOLS |www.nature.com/nprot 15
Identification of nearby heterozygous SNPs by Ensembl BioMart and validation in unedited
cells or organism ● Timing 2–4 d
22 Open Ensembl BioMart (https://www.ensembl.org/info/data/biomart/index.html) and select the
Ensembl Variation 102 database with the respective dataset for your species, e.g., ‘Human Short
Variants (SNPs and indels excluding flagged variants) (GRCh38.p13)’. Specify filters to define a
region of 10 kb around the cut site and a global MAF of ≥0.3 under general variant filters.
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c CRITICAL STEP The frequency of genomic variation strongly varies between different loci. We
recommend performing the analysis with ~5–10 different SNPs on each side of the cut site to have a
sufficient chance of identifying heterozygous SNPs in the ‘parent’ cell line or organism. If the above-
mentioned filters do not yield enough variants, double the size of the analyzed genomic region and
lower the cutoff for the global MAF by 0.1; repeat these adjustments if necessary.
23 Once the potential heterozygous SNPs are identified, download the flanking sequence around the
SNP from Ensembl.
c CRITICAL STEP Ensure that the genomic coordinates from the database are identical to those
used in BioMart by using the same version of the edited genome (GRCh38.p13 for human cells).
24 Using the downloaded sequence, design primers for a 300–500 bp PCR around the SNP as
described in the PCR optimization above (Step 3) and assemble a 50 μl PCR reaction using gDNA
from the unedited ‘parent’ cell line as described in the table below. We recommend testing one
primer pair at each locus first and designing more primers only if necessary.
Components Amount Final concentration
Genomic DNA 50 ng 1 ng/μl
2× OneTaq Quick-Load Master Mix 25 μl 1×
Forward primer (10 μM) 1 μl 0.2 μM
Reverse primer (10 μM) 1 μl 0.2 μM
DNase-free H2O To 50 μl
25 Run the following program on a thermocycler:
Step Temperature (ºC) Time No. of cycles
1. Initial denaturation 94 2 min 1×
2. Denaturation 94 30 s 35×
3. Annealing 60 (50–70) 30 s
4. Extension 68 1 min/1,000 bp
5. Final extension 68 5 min 1×
6. Hold 10 Until ready to process 1×
26 Perform electrophoresis by analyzing 3 μl of the reaction mix as described above (step 6) and
inspect PCR bands. If a single strong band is present at the expected size, purify the remaining 47 μl
of PCR reaction using a PCR clean-up kit, such as NucleoSpin Gel and PCR Clean-Up (Macherey-
Nagel), according to the manufacturer’s instructions. If the band size is incorrect or more than one
band is present, perform a gradient PCR with annealing temperatures between 50–70 °C. If this
does not improve the PCR result, design and order new primer pairs (step 3).
? TROUBLESHOOTING
Fig. 3 | Anticipated results for OnTE detection—example of CRISPR editing at the APPSwe locus in human iPSCs. a, Overview of CRISPR editing and
positions of primers and probes for two independent qgPCR assays at the APPSwe locus. fw, forward; rv, reverse. b, PCR optimization at the APPSwe
locus with combinations of three forward and three reverse primers at increasing annealing temperatures (50–70 °C in 4 °C steps), analyzed on a 2%
(wt/vol) agarose gel. Two primer combinations (A and E) were selected for the qgPCR assays 1 and 2 shown in e. c, qPCR amplification plot of human
TERT reference gene for two NHEJ-/RNP-edited clones and the unedited ‘parent’ line A18944. (ΔRn = normalized reporter fluorescence signal –
baseline). Data are represented as means ± s.e.m. (n = 2). d, qPCR amplification plot of APPSwe qgPCR assay 1 for two NHEJ-/RNP-edited clones and
the unedited A18944 line. Note shift in ΔRn for clone P1D22 indicating an OnTE. Data are represented as means ± s.e.m. (n = 2). e, qgPCR analysis
with two independent assays reveals clones with decreased allele copy number for HDR-clones edited by plasmid delivery of editing components
(top), NHEJ clones with plasmid delivery (middle) and NHEJ clones with RNP delivery (bottom). Edited clones were genotyped beforehand to confirm
insertion of the APPSwe mutation for HDR editing or generation of putative homozygous indels for NHEJ editing. Values were normalized to the
unedited ‘parent’ cell line A18944. Highlighted clones (*) also shown in c and d (P1C2 + P1D22) or f–h (P1G9). f, Sanger sequencing traces from
nearby SNP sequencing for unedited line and APPSwe LOH clone P1G9. g, Overview of ±15 SNPs analyzed around the APPSwe locus by the Illumina
Global Screening Array v.2 genotyping chip and zygosities in unedited cell line A18944 and LOH clone P1G9 (HDR-plasmid editing). h, SNP microarray
analysis determining log R ratios and B-allele frequencies in control and APPSwe clone P1G9 (HDR-plasmid editing) reveals LOH from the cut site to the
end of the long arm of chromosome 21. iPSC line A18944 (RRID: CVCL_RM92) has been validated by fingerprinting, pluripotency assays and
karyotyping, and for absence of mycoplasma. e (upper two graphs), f and h are modified from ref. 13.
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27 Sanger sequence the purified PCR product and determine the zygosity of the SNP in the unedited
‘parent’ line. Continue until you have identified at least one heterozygous SNP on each side of
the cut site.
? TROUBLESHOOTING
LOH analysis by SNP genotyping in edited cells or organisms to exclude those with
OnTEs ● Timing 1 d
28 Using the same assay, analyze edited cell lines to check if SNP zygosities have changed from
heterozygous to homozygous. Loss of heterozygous SNPs indicates occurrence of LOH; exclude all
clones or animals with LOH from further analysis.
Analysis of gDNA on genome-wide SNP microarray ● Timing 3 d
c CRITICAL The SNP microarray chip needs to match the edited organism and provide sufficient
coverage in the edited region. Targeted content chips (e.g., exome chips, panel chips) are not suitable.
We used the Illumina Global Screening Array v.2 genotyping chip for analysis in human cells, which
provides reasonably dense and well-balanced genome-wide coverage at a relatively low price (about US
$50). A chip suitable for mouse could be the GGP GIGA-MUGA-24, which provides more than 143,000
SNPs. In general, the number of informative SNPs depends very much on the animal strain and
subspecies used. Therefore, applicability needs to be determined for each individual experiment.
29 Check suitability of chip. To confirm that the selected chip has sufficient coverage in the edited
genomic region, download the chip manifest file detailing available variants and chromosomal
positions as a CSV file from the manufacturer’s webpage (e.g., ftp://webdata2:webdata2@ussd-ftp.
illumina.com/downloads/productfiles/global-screening-array/v2-0/gsa-24-v2-0-A1-manifest-file-
csv.zip).
30 Open the file with Excel and sort for chromosome and position to locate your editing site.
31 Check for available variants around the targeted site. If there are no biallelic variants available on
the chip within ±10–50 kb of the editing site, we suggest finding a chip with better SNP coverage in
the respective area.
32 Whole-genome amplification. Measure DNA concentration by Qubit and check integrity with 1 µl
DNA on a 0.8% (wt/vol) agarose gel. Add 4 µl gDNA (30–100 ng/µl) to a 96 well 0.8 ml microplate
(MIDI plate).
c CRITICAL STEP The microarray genotyping workflows of the leading chip manufacturers
Illumina and Thermo Fisher Scientific require high-molecular-weight DNA as input because all
protocols start with a whole-genome amplification. Accurate quantification is crucial and therefore
ultraviolet measurement methods are not recommended because RNA or extraction contaminants
may lead to an overestimation of the quantity. Instead, methods using fluorophores specific for
double-stranded DNA, e.g., Qubit assays, give more reliable concentration data.
c CRITICAL STEP In the first SNP microarray experiment, include one unedited control gDNA
sample for analysis to be able to detect changes in edited cell lines or organisms. In subsequent
experiments with the same original cell line, no further controls are required.
33 Thaw MA1, MA2 and MSM buffers from the Illumina kit and mix by inverting. Preheat the
Illumina hybridization oven to 37 °C.
34 Dispense 20 µl MA1 and 4 µl 0.1 N NaOH into each well using a multichannel pipette, seal the plate
with adhesive foil and vortex at 1,500 r.p.m. for 1 min.
35 Incubate for 10 min at room temperature.
c CRITICAL STEP Incubation time must not exceed 12 min.
36 Remove adhesive foil, add 34 µl MA2 and 38 µl MSM into each well using a multichannel pipette
with filter tips, seal the plate with a cap mat and mix by inverting. Centrifuge at 280g for 1 min at
room temperature and incubate the plate in the Illumina hybridization oven at 37 °C for 20–24 h.
37 Fragmentation. Thaw the FMS tube and mix by inverting. Preheat a heat block with a MIDI plate
insert to 37 °C.
38 Remove the MIDI plate from the hybridization oven and centrifuge at 280g for 1 min at room
temperature. Remove the cap mat, add 25 µl FMS using a multichannel pipette with filter tips, seal
the plate again with the same cap mat, vortex for 1 min at 1,500 r.p.m. and centrifuge at 280g for
1 min at room temperature.
39 Place plate on the 37 °C heat block for 1 h.
c CRITICAL STEP Incubation time must not exceed 2 h.
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40 Precipitation. Thaw PM1 at room temperature, remove the cap mat from the MIDI plate and add
50 µl PM1 to each well with a multichannel pipette. Seal the plate with the same cap mat, vortex at
1,500 r.p.m. for 1 min and centrifuge at 280g for 1 min at room temperature.
41 Incubate the plate in the 37 °C heat block for 5 min followed by centrifugation at 280g for 1 min at
room temperature. Remove the cap mat and add 155 µl 2-propanol to each well using a
multichannel pipette. Seal with a new cap mat and mix by carefully inverting 10 times.
42 Incubate the plate in a refrigerator at 4 °C for 30 min.
43 Precool centrifuge to 4 °C and centrifuge the plate at 3,000g for 20 min at 4 °C.
c CRITICAL STEP Check if blue pellets are visible at the bottom of each well at the end of the
centrifugation. If this is not the case, repeat this step.
44 Remove the cap mat and drain the liquid by inverting the whole plate. Put the plate on an absorbent
pad and smack down several times to remove liquid drops. Leave the inverted plate on a tube rack
for 1–2 h to air dry the pellets.
c CRITICAL STEP Keep the plate inverted all the time to avoid contamination until the pellets are
dry. Do not dry pellets longer than 2 h otherwise it may be difficult to resuspend them.
45 Resuspension. Preheat the Illumina hybridization oven to 48 °C. Turn on the heat sealer and thaw
RA1 in a 25 °C water bath. Pipette 7 ml RA1 into a reservoir.
46 From the reservoir add 23 µl RA1 to each well using a multichannel pipette, seal the plate with a
heat seal foil on a heat sealer at 165 °C for 5 s and incubate the plate in the Illumina hybridization
oven at 48 °C for 1 h.
47 Remove the plate from the oven, vortex at 1,700 r.p.m. for 1 min and centrifuge at 280g for 1 min at
room temperature.
j PAUSE POINT The plate can be stored at −20 °C for up to 24 h or at −80 °C for up to 3 months.
48 Hybridization to array. Preheat a heat block with a MIDI plate insert to 95 °C and the Illumina
hybridization oven to 48 °C. Set rocker speed to 5.
49 Assemble the Illumina hybridization chambers according to the Infinium HTS Assay Reference Guide
(https://support.illumina.com/content/dam/illumina-support/documents/documentation/chemistry_
documentation/infinium_assays/infinium-hts/infinium-hts-assay-reference-guide-15045738-04.pdf).
You need one chamber for each 96-well plate, i.e., four bead chips. Pipette 400 µl PB2 into each of the
eight chamber reservoirs, close the chamber with the lid and leave it until chips are loaded with DNA.
50 Place the plate from step 49 on the 95 °C heat block for 20 min, let it cool down on the bench for
30 min and centrifuge at 280g for 1 min at room temperature. Remove the heat seal.
51 Place four Illumina GSA bead chips on two alignment fixtures and cover the fixtures with the Robot
Tip Alignment Guide-G.
52 Place the MIDI plate and the prepared alignment fixtures on the pipetting robot.
53 Start the program Illumina Automation Control and select ‘MSA3-Hyb Multi BC2’. Pipetting one
96- well plate onto four bead chips takes ~25 min.
54 Place each bead chip in the prepared Illumina hybridization chamber. Cover the chamber with the
lid by closing all four clamps. You will need four bead chips for 96 samples.
55 Place the hybridization chamber in the prepared Illumina hybridization oven and incubate at 48 °C
for 16–24 h.
56 Prepare the XC4 reagent by adding 330 ml absolute ethanol. Shake the bottle vigorously for 15 min
and leave it on the laboratory bench at room temperature overnight.
57 Washing, extension, staining. Thaw LX1, X2, SML, ATM and EML tubes (one tube each for four
bead chips). Prepare the 95% (vol/vol) formamide/1 mM EDTA solution by mixing 23.75 ml
formamide, 1.2 ml water and 50 µl 0.5 M EDTA.
! CAUTION Formamide is toxic! Wear full PPE.
58 For four bead chips fill one Multi-sample BeadChip alignment fixture with 150 ml PB1 and place
four black frames into it. Fill two wash dishes with 200 ml PB1 each.
59 Remove the hybridization chamber from the oven and let it cool on the laboratory bench for 30 min
before opening.
60 Place LX1, X2, SML, ATM and EML tubes in the pipetting robot and remove all caps. Place three
reservoirs with 15 ml 95% (vol/vol) formamide/1 mM EDTA, 10 ml RA1 and 50 ml XC3 in the
pipetting robot.
61 Turn on the water circulator and set the temperature to 44 °C.
62 Submerge the wash rack in one wash dish with 200 ml PB1. Open the hybridization chamber,
remove one chip at a time, remove the seal on the chip starting with a corner on the barcode end
and immediately place the chip into the wash rack in PB1.
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63 After all chips are in the wash rack, move the rack up and down for 1 min. Move the wash rack to
the second wash dish with 200 ml PB1 and repeat.
64 Place each chip into one black frame from the Multi-Sample BeadChip Alignment Fixture from
step 58. Place a clear LCG spacer onto the top of each chip and place the alignment bar onto the
fixture. Place a glass back-plate on each chip and attach the metal clamps to the flow-through
chambers.
65 Remove the flow-through chambers from the fixture and trim the ends of the spacers
with scissors.
c CRITICAL STEP Do not let the bead chips dry. Bead chips should always be in PB1.
66 Start the program Illumina Automation Control and select ‘XStain Tasks | XStain LCG BeadChip’.
Enter the number of bead chips and make sure that you placed all items properly on the robot bed.
67 Click ‘Run’. Enter the stain temperature indicated on the SML tube and when the temperature
probe registers 44 °C, click ‘OK’.
68 When prompted, place each assembled flow-through chamber in the chamber rack and click ‘OK’.
The entire program takes 2–3 h.
69 Fill 310 ml PB1 in a wash dish and submerge the staining rack. Remove the assembled flow-through
chambers from the robot, disassemble each flow-through chamber, remove the spacer and place the
bead chip in the staining rack. Move the rack slowly up and down 10 times and leave it in PB1 for
another 5–30 min.
70 Fill 310 ml XC4 from step 56 in a wash dish. Immediately remove the staining rack from the PB1
dish, place it directly into the XC4 dish, move the rack slowly up and down ten times and leave it in
XC4 for additional 5 min.
71 Remove the staining rack from the XC4 dish and place it on a tube rack. Remove the bead chips
from the staining rack and put them on another tube rack.
72 Put all bead chips into a vacuum desiccator, apply the vacuum and dry for 60–90 min. Remove each
bead chip and clean the underside with a wipe soaked with ethanol.
c CRITICAL STEP The bead chips are now ready for scanning.
j PAUSE POINT The bead chips can be stored in the dark at room temperature for several weeks
before scanning.
73 Scanning. Download dmap files from Illumina with the Decode File Client. There is one dmap file
folder per bead chip.
74 Turn on the iScan scanner. Warm up for 30 min and place up to four bead chips onto one carrier.
75 Start iScan Control software and click ‘Start’. The iScan tray opens. Place the carrier onto the tray
and select ‘Scanner | CloseTray’. Click ‘Next’. Use the Infinium LCG scan setting. Scanning time is
~30 min for one bead chip.
76 Data are stored in the ScanData folder. There is one folder per bead chip. For data analysis you will
need the .idat files. There are 48 .idat files per bead chip.
Processing of microarray data and analysis of log R ratios and B allele frequencies to
exclude cells or organisms with OnTEs ● Timing 2 h
c CRITICAL The following steps are valid for all Illumina genotyping chips. Procedures for Affymetrix
chips might differ.
c CRITICAL Ensure that in the regional settings of your operating system, the decimal symbol
is set to ‘.’.
77 Before starting the chip analysis, acquire the following chip-specific files from the Illumina support
center webpage (e.g., https://emea.support.illumina.com/downloads/infinium-global-screening-arra
y-v2-0-product-files.html for GSAv2.0):
● Bead pool manifest files (.bpm) that contain information about SNP/probe content on the
BeadChip.
● Cluster files (.egt or .egtp), which have reference cluster information for each interrogated locus.
c CRITICAL STEP Please verify that you have downloaded the correct files for the chip, as there
will be differences, even between different versions of the same chip.
78 After genotyping, acquire the following files from the chip analysis:
● Raw intensity data files (.idat files).
● Sample sheets (.csv files that contain sample information, such as plate ID, cell ID, gender, and so
on; open with a text editor (not Excel) and confirm that file paths fit to the location of the files on
your computer).
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79 Open GenomeStudio and start a new Genotyping project. Genome studio will ask for a Project
Repository folder in which to save analysis files and a project name; the sample sheet and raw data
files should be provided in a Data Repository folder, and the bead pool manifest file in a Manifest
Repository folder. In the next dialog box, give the location of the cluster file from Step 77, and
‘import cluster positions’.
80 Choose to ‘Calculate Sample and SNP Statistics’ under ‘Project Creation Actions’ and click ‘Finish’.
Automatic clustering will be performed by GenomeStudio during the manual data loading step.
? TROUBLESHOOTING
81 Go to ‘samples table’ (usually lower left in GenomeStudio) and confirm the gender of your samples
by right-click and ‘Estimate Gender’.
c CRITICAL STEP If there is a gender mismatch, review the sample sheet and confirm that the
samples were matched correctly. If the error persists, samples may have been mixed up.
82 Exclude samples with <95% call rate and select ‘Analysis/Update SNP statistics’.
83 Select the ‘SNP Table’ tab and filter based on ‘Call Freq’ > 0.95.
84 In the ‘Full Data Table’ tab filter SNPs (filter rows) based on the chromosome of interest.
? TROUBLESHOOTING
85 Add Filter to display only SNPs with GenTrain score >0.7.
? TROUBLESHOOTING
86 Add Filter ‘Name lacks cnv’ to display only biallelic SNPs.
87 In ‘Column chooser’, for each sample, display ‘B Allele Freq’, ‘Log R Ratio’ and ‘GType’.
88 Generate a scatter plot using the ScatterPlot function. Select ‘Position’ as the x-axis and, after
selecting individual sample in ‘Columns’, select ‘B Allele Freq’ as the y-axis in ‘Sub columns’. The
resulting image displays frequencies of A and B alleles along the selected chromosome. Regions of
potential LOH are characterized by long stretches of homozygous SNPs.
89 Generate a scatter plot using the ScatterPlot function. Select ‘Position’ as the x-axis and ‘Log R ratio’
as the y-axis for each sample of interest. The resulting image displays copy number information
about all assayed SNPs along the selected chromosome. If regions of LOH have normal copy
numbers ~0 to ±0.25, the aberration is a LOH; if copy number is increased or decreased, the area is
duplicated or deleted, respectively.
90 Select ‘export displayed data to a file’. Select all visible rows.
91 The exported tab-separated file can be loaded into Excel or statistical software for further
processing.
Troubleshooting
Troubleshooting advice can be found in Table 1.
Table 1 | Troubleshooting table
Step Problem Possible reason Solution
6,26 PCR does not work efficiently
with any tested primer
combination and
temperature
Target DNA concentration too low Increase amounts of gDNA in the PCR reaction
Poor DNA quality or integrity Check for gDNA degradation by gel electrophoresis. gDNA
can also be contaminated by components from the lysed cells,
such as salts or nucleases, or components of the purification
kits, including incompletely inactivated Proteinase K, SDS,
EDTA or chaotropic salts, which can affect photometer
readings. Carefully perform all purification steps according to
the manufacturer’s protocol and check the 260/280 ratio
using a spectrophotometer. If required, further purify gDNA by
ethanol precipitation
Locus difficult to amplify by
standard PCR
Check locus for overall GC content and hard-to-amplify
regions, such as single-base stretches. These issues can often
be solved by changing the polymerase (e.g., to NEB Q5,
Agilent Herculase, KAPA Master mix), adding high-GC
enhancer (comes with Q5), adding 1–5% (vol/vol) DMSO or
moving primers to avoid difficult regions
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Table 1 (continued)
Step Problem Possible reason Solution
7,27 Sanger sequencing does
not work
Poor DNA quality Purify PCR product using recommended kit
Inappropriate amounts of DNA Check for presence of PCR product by gel electrophoresis
after purification
Accurately determine DNA concentration by
spectrophotometer or fluorometer measurements and dilute
to concentration recommended by Sanger sequencing
provider
Locus difficult to sequence Use primer for sequencing lying inward of PCR product
Perform TOPO cloning of PCR products into a plasmid vector.
Note that abundance of alleles may vary in the TOPO clones.
Heterozygous events will therefore be more difficult to detect
17 Standard deviation of
replicates is >0.2
Unequal amounts of reaction mix in
each well
Thoroughly mix samples before pipetting
Ensure accurate pipetting for each sample, which can be
achieved by not reusing pipette tips for the same sample or
using low-retention pipette tips. If available, electronic
pipettes can also help to improve precision of pipetting
Unequal detection by qPCR
machine
Run qPCR machine maintenance to ensure equal detection of
all wells; if problem persists, avoid areas with unequal
detection, which can occur especially toward the edges of
the plate
Ct values are >30 Too little gDNA within the reaction Increase gDNA concentration
Inhibitors of PCR reaction present Purify gDNA using recommended kit
No template control gives
a signal
Contamination of reaction mix Repeat qgPCR using all fresh reagents and filter tips for
pipetting
If available, using a dedicated and/or ultraviolet-treated area
for qPCR reactions can further minimize risk of contamination
No amplification detectable
in all or some samples
Issues with primers, probe,
template, buffers or qPCR machine
See detailed infomation on qPCR basics in Real-time PCR
Handbook (https://www.thermofisher.com/content/dam/
LifeTech/global/Forms/PDF/real-time-pcr-handbook.pdf),
and troubleshooting in protocol by Weissenborn et al.33 for
detailed discussion and suggestions
18 Copy number values strongly
vary between samples and
are not close to values of ‘1’
or ‘2’ allele numbers
Varying integrities of gDNA
samples
Repeat gDNA extraction of all samples together and make
sure to treat all samples exactly the same
Unequal amounts of gDNA in
each sample
For precise determination of gDNA concentrations, use, for
example, a Qubit fluorometer instead of a spectrophotometer.
Take extreme care with accurate pipetting when diluting
samples to the working concentration
Restricted accessibility of qPCR
assay to gDNA
Predigestion of gDNA with a restriction enzyme that does not
cut within the qPCR amplicon can increase accessibility of
primers to DNA and improve accuracy of results
NHEJ clones have copy
number values <1
Probe overlaps with indel Redesign qgPCR assay to prevent overlap of probe with indel
19 More than two bands are
visible on agarose gel
Unspecific amplification of
qPCR assays
Unspecific amplification occurring in multiple samples could
affect the efficiency of target amplification and therefore
cause unreliable results. Adjusting qPCR conditions such as
input gDNA amount or primer concentrations or eventually
exchanging primers should be tested
Sample has OnTEs at edited locus Multiple bands in a single sample might be caused by OnTEs
that occurred within the genotyping PCR amplicon. This clone
should therefore be excluded
27 No tested SNPs are
heterozygous in the
unedited line
The edit was done in a region of low
variation
Expand the region in which the zygosity of SNPs is
investigated by doubling the size of the analyzed genomic
region and lowering the cutoff for the global MAF by 0.1. In
principle, there is no limit to how far away from the cut site
LOH can be investigated; however, analyzing heterozygous
SNPs close to the cut site can exclude occurrence of smaller
regions of LOH
Perform SNP microarray to obtain genome-wide SNP profile
An inbred organism was used Perform editing in a cell line or animal strain with higher
genomic variation
LOH analysis is not necessary for inbred organisms
Table continued
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Timing
Step 1, CRISPR editing in cells or organisms of interest: 1–3 months, depending on organism
Step 2, gDNA extraction: 2 h
Steps 3–7, design and optimization of 300–450 bp genotyping PCR: 1 d
Step 8, identification of cells or organisms with desired edit by RFLP assay and Sanger sequencing: 2–3 d
Steps 9 and 10, design of labeled oligo for qgPCR: 1 h
Steps 11–20, analysis of edited cells or organisms by qgPCR to exclude those with OnTEs: 1 d
Step 21, select methods to exclude LOH: 1 h
Steps 22–27, identification of nearby heterozygous SNPs by Ensembl BioMart and validation in unedited
cells or organisms: 2–4 d
Step 28, LOH analysis by SNP genotyping in edited cells or organisms to exclude those with OnTEs: 1 d
Steps 29–76, analysis of gDNA on genome-wide SNP microarray: 3 d
Steps 77–91, processing of microarray data and analysis of log R ratios and B allele frequencies to
exclude cells or organisms with OnTEs: 2 h
Anticipated results
Thorough quality control after genome editing is essential to ensure reliability of results based on
edited cells or organisms (Box 2). The presented protocol describes detection of OnTEs in cells or
animals after NHEJ- and HDR-mediated CRISPR–Cas9 genome editing. As an example, we
demonstrate our OnTE quality-control assays in human iPSCs edited at the APP ‘Swedish’ locus
(APPSwe; Fig. 3a), which is mutated in patients with early-onset Alzheimer’s disease34. Using our
guidelines, the protocol can be adapted to other edited loci in iPSCs and also to other human and
non-human cell lines and organisms.
Before performing OnTE detection, successful genome editing should be confirmed in single-cell
clones or organisms using a 300–450 bp genotyping PCR. Optimal PCR conditions should be
identified by testing combinations of different forward and reverse primers at different annealing
temperatures, which usually yields at least one suitable combination (Fig. 3b). Then, a matching
fluorescently labeled probe should be designed that can be used in the following qgPCR analysis. The
underlying principle of the qgPCR is that a lower number of intact alleles at the edited locus leads to
lower fluorescence values during target amplification and therefore an increase of the Ct value of the
target-specific qPCR assay. As template amount and quality can vary between different samples,
leading to varying PCR amplification of the target, a reference assay, such as TERT for human cells, is
used in the same amplification reaction for (Ct) normalization. If Ct values of the reference assays do
Table 1 (continued)
Step Problem Possible reason Solution
80 GenomeStudio fails to locate
intensity data
Incorrect directory is provided Usually, the intensity files (.idat) are stored in folder(s) with
names consisting of just numbers that refer to the beadchip ID.
The directory provided to GenomeStudio needs to be the folder
that contains all subfolders that store the actual .idat files. Also,
using a text editor, check in the Samplesheet if the right directory





GenomeStudio fails to load
certain samples
Incorrect Samplesheet Using a text editor, check in the Samplesheet if the right
directory is provided and if all samples are included in the
Samplesheet
84,85 GenomeStudio does not
perform correct filtering
Conflicting regional system settings Open the Windows Start menu and click Control Panel. Open
the Regional and Language Options dialog box. Click the
Regional Options tab. Click ‘Customize/Additional settings’
(Windows 10). Type a period into the ‘Decimal separator’ box
(.) Click ‘OK’ twice to confirm the change
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not differ between samples (Fig. 3c), samples without OnTEs will have the same Ct value as the edited
control. Samples with OnTEs will vary by one cycle (Fig. 3d). In case of differing Ct values for the
reference assay (e.g., due to varying gDNA amounts in different samples), samples are normalized by
determining the ΔΔCt value, which then directly correlates with the number of intact alleles at the
target locus (Fig. 3e). For our human iPSCs edited at the APPSwe locus we observed clones with
OnTEs at varying frequencies, ranging from 17 to 57% depending on the editing system (HDR and
plasmid versus NHEJ and RNP, respectively). These clones need to be excluded from further analysis.
In general, OnTE frequency may also vary strongly depending on the edited locus or organism.
After successful exclusion of OnTEs such as large deletions or complex rearrangements by qgPCR,
one should continue with LOH analysis by confirming the presence of heterozygous SNPs on both
sides of the target locus. This can be done either by nearby SNP sequencing or SNP microarrays
(Box 1). Again, frequencies of LOH occurrence may strongly depend on the target locus or organism.
Furthermore, the number of affected SNPs might also range from only one or a few SNPs, to entire
chromosome arms. To exclude the occurrence of LOH at the target site, it is sufficient to genotype
one SNP on each side of the cut site after editing, but SNP sequencing can also be expanded further
around the target locus to also determine the dimension of larger regions of LOH (Fig. 3f). If LOH
detection by SNP microarray analysis is desired, it should first be confirmed that the number and
density of SNPs around the target locus detected by the used chip is sufficient (preferably multiple
variants within ±10–50 kb). The Illumina Global Screening Array v.2 genotyping chip we used will
analyze on average one SNP approximately every 4.4 kb. However, only a subset of analyzed SNPs
will be heterozygous in the unedited cell line and only these are useful for detection of LOH in this
area (Fig. 3g). In cases of copy-neutral LOH detected by SNP microarray analysis, the log R ratio
would stay constant due to unchanged copy numbers, but all heterozygous signals in B-allele fre-
quency would be lost (Fig. 3h provides an example of LOH from the cut site to the chromosome end).
Since LOH can affect gene expression, clones with LOH around the target site need to be excluded
from further analysis. LOH may also occur distal to the edited locus, but because such cases are
probably not caused by Cas9 chromosome cleavage at the targeted site, they would not be classified as
OnTEs. In principle, distal LOH could be caused by off-target activity of Cas9, but also by Cas9-
independent chromosomal rearrangements that occur spontaneously.
Data availability
Data that support the findings of this study are available in Mendeley Data, https://doi.org/10.17632/
v3xg37d77t.1
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This thesis deals with a widely overlooked issue in the field of CRISPR genome editing:  the 
occurrence of deleterious OnTEs that frequently escape standard quality controls. We show 
that this is a widespread problem in genome-edited human iPSCs and develop simple tools 
for their reliable detection (Figure 8). However, a lot remains to be done to entirely prevent 
OnTEs from compromising the reliability of CRISPR-based studies: First, we hope to achieve 
a better awareness of this problem by CRISPR users, which should then lead to widespread 
implementation of our detection methods. In a next step, it would be beneficial to identify 
factors that influence OnTE occurrence to unravel underlying molecular mechanisms. This 
could eventually help to establish guidelines for genome editing protocols that prevent OnTE 




Figure 8: Overview of OnTE detection framework after CRISPR editing. Genome editing using the 
CRISPR/Cas9 system may induce large deletions, large insertions or complex rearrangements around 
the target site (left). These can be identified using qgPCR that determines the number of intact alleles. 
Additionally, the repair of DNA DSBs may lead to regions of LOH around the cut site that can be 
identified using SNP genotyping by Sanger sequencing or SNP microarrays (right).  
 
4.1 The problem of CRISPR-induced OnTEs requires more attention 
The first step towards solving the problem of undetected OnTEs is its recognition as a severe 
problem by the genome-editing community. A recent study (Kosicki et al., 2018) has created a 
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lot of attention and researchers were “calling for greater caution when using it in clinical 
contexts” (Baumann, 2018), as many realized that “Some of these changes could be the first 
hits that cause cells to eventually become neoplastic” (Leslie, 2018). However, the problem of 
OnTEs is still widely overlooked in the CRISPR field and measures for their detection are 
missing in over 90% of recently published papers on edited iPSCs1. This thesis clearly 
demonstrates the severity of this issue: we identified OnTEs in human iPSCs at multiple loci 
in up to 40% of clones. Thus, it is conceivable that affected clones are sometimes used in 
similar CRISPR-based studies, which might lead to data misinterpretation and false 
conclusions. We therefore tried to alert more researchers to this problem by showing an 
example of deleterious consequences of undetected OnTEs: Using an in vitro Alzheimer’s 
disease model, we show that monoallelic OnTEs can lead to a significant reduction of 
expression of the targeted gene. This reduction could hamper with pathogenic phenotypes and 
therefore affect the reliability of the entire experiment.  
 
4.2 Preventing undetected OnTEs by using reliable detection methods  
The low level of awareness about the issue of undetected OnTEs in the CRISPR community 
leads to a lack of on-target quality control measures in most studies. We reasoned that this is 
to a great extent due to the fact that there are no suitable methods available for this purpose. 
In this study, we therefore developed a new OnTE detection technology that is reliable, simple, 
and broadly applicable, which we hope will facilitate its widespread application after genome 
editing. The advantages and limitations of our methods are discussed in the following, along 
with a comparison with alternative methods that were previously used in the field.  
 
4.2.1 Advantages of the presented OnTE detection technology 
The first advantage of our OnTE detection technology is that the entire workflow can be 
performed using PCR amplification, gel electrophoresis, Sanger sequencing and qPCR, which 
are all standard methods in molecular biology labs that are typically available to all CRISPR-
users. In addition, we provide an alternative for LOH detection by genome-wide SNP 
microarrays that requires access to specific equipment but enables more high-throughput 
analysis.  
Second, the combination of only two methods, qgPCR analysis and SNP genotyping, allows 
reliable detection of the major types of OnTEs after CRISPR editing: qgPCR analysis combines 
quantification with genotyping and can therefore directly identify copy number changes at the 
target locus that can be caused by large deletions, insertions, or complex rearrangements. For 
detection of LOH after editing, each researcher can choose between two different methods 
 
1 determined by parsing all papers from 2019 on PubMed that had the search terms ‘iPS*’ and  ‘CRISPR’ in title or abstract and that performed 
compatible editing experiments. 
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according to their advantages and disadvantages: Briefly, nearby SNP genotyping is solely 
based on PCR and Sanger sequencing and is therefore a cheap and simple assay. SNPs 
zygosities have to be determined experimentally, which can be laborious but also allows more 
flexibility with regard to the analyzed area. LOH detection by SNP microarrays is more 
expensive and requires special equipment but offers a fast option to test multiple samples in 
parallel, also with different edits. The genome-wide analysis can also serve as additional check 
for other large chromosomal aberrations.  
A third advantage is that the entire analysis is performed using only purified genomic DNA from 
the edited sample and controls, which allows broad use of our protocol in various cell lines or 
organisms that all might be affected by OnTEs. 
Lastly, our technology is widely applicable to different types of genomic changes after NHEJ- 
as well as HDR-mediated editing (see below). 
 
4.2.2 Comparison with other methods 
Previous studies have used different tools for OnTE detection after CRISPR editing, however, 
these tools have certain drawbacks that do not make them suitable for reliable and widespread 
application by all CRISPR users:  
Primer-walk PCR, which we have also tested in this study, is very laborious and does not 
produce reliable results, as large or complex OnTEs might not be detectable by PCR reactions. 
Furthermore, we also tested standard qPCR assays with a length of maximal 150 bp, but these 
failed to detect clones with OnTEs that did not directly overlap with the cut site. Droplet digital 
PCR, similar to qPCR, quantifies a PCR reaction around the edited locus, but this method 
additionally requires special equipment and complex data analysis. Furthermore, all of the 
above-mentioned methods do not detect LOH. Next, array-based technologies such as 
comparative genomic hybridization (CGH) or SNP microarrays are frequently used to detect 
chromosomal aberrations genome-wide, but their resolution is too low for detection of smaller 
changes of few kb. Lastly, next-generation sequencing technologies enable reliable detection 
of OnTEs with high sensitivity, but they are not available to all CRISPR users due to their high 
cost and complex data analysis. Overall, our technology outcompetes previously used 
technologies due to its simplicity and broad applicability, but it certainly also has limitations. 
 
4.2.3 Limitations of the presented OnTE detection technology 
In this study, we have developed methods for quality control analysis of individual cell lines or 
organisms to ensure locus integrity after genome editing. Our methods, however, do not allow 
analysis of OnTE prevalence in genomic DNA from pooled samples. Such an application could 
prove very useful to further investigate the effect of different genome editing components or to 
test more loci, as it is described below.  
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Furthermore, in this study, we have analyzed single-cell clones edited by the NHEJ - as well 
as the HDR pathway, introducing small sequence changes up to 10 bp. In these cases, the 
qgPCR amplicon can easily span the edited locus and the unedited ‘parent’ cell line can be 
used as control. We have, however, not tested our methods after introduction of larger 
changes, e.g., after insertion of fluorescent protein tags. Here it is not possible to perform 
qgPCR analysis using our design principles, as the PCR-product cannot entirely span the 
edited site. But the same principle, quantification of PCR reactions, might also be applicable 
to these cases with further adaptations. In contrast, LOH analysis by SNP genotyping is not 
affected by the size of the edit. 
Lastly, qgPCR analysis does not detect genomic alterations that do not affect copy numbers 
such as translocations or inversions of the entire genotyping PCR amplicon. 
 
We hope that the OnTE detection tools we present in this thesis will provide a valuable 
resource for the genome editing field and will soon be used by many researchers. The next 
steps for research on OnTEs should then aim towards better understanding why OnTEs occur 
and how their occurrence can be avoided.  
                  
4.3 Occurrence of OnTEs is a widespread problem 
Understanding the general extent of the problem of OnTEs is an important task for the genome 
editing field. This would help to develop guidelines in which cases it is necessary to perform 
suitable quality control experiments.  
Previous studies have identified OnTEs in mice and one immortalized human cell line and our 
findings clearly illustrate the universality of this problem in human iPSCs. This suggests 
widespread conservation of involved molecular mechanisms, but it is important to confirm this 
hypothesis in further cell lines and model organisms that are frequently used for genome 
editing. It is likely that there will also be organism- and cell line-specific differences for OnTE 
prevalence due to varying activities of alternative DNA repair pathways. For example, it has 
been shown previously that mouse and human stem cells have higher rates of DSB repair by 
the microhomology-mediated end-joining (MMEJ) pathway (Allen et al., 2019), which accounts 
for large deletions or insertions at the edited site (see below). Furthermore, all studies, 
including ours, have only applied CRISPR-based tools for investigation of OnTEs after editing. 
It is therefore still unclear if other systems, e.g., based on TALEN or ZFN nucleases are 
affected likewise. However, it is likely that OnTEs are also a problem using these systems, as 
they also rely on DSB induction, which is most likely the dominant factor for OnTE occurrence, 
rather than the type of used nuclease. 
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As mentioned above, the OnTE detection methods developed in this thesis can be applied to 
different cell lines, organisms and editing systems and can therefore be very helpful to address 
questions surrounding OnTE occurrence.  
 
4.4 Unraveling the molecular mechanisms underlying OnTE occurrence  
When taking a closer look at breakpoint junctions of large deletions around the cut site, we 
and others (Owens et al., 2019) noticed that these were predominantly located at sites of 
microhomologies of 2-5 bp. This strongly indicates involvement of the MMEJ pathway, a less 
common alternative for DSB repair known to induce large deletions or insertions (Sfeir & 
Symington, 2015). In support of this hypothesis, experiments in mouse ESCs have shown a 
decreased frequency of large deletions upon deficiency of MMEJ repair genes (Kosicki et al., 
2020). A pathway responsible for chromosomal rearrangements leading to copy-neutral LOH 
has - to our knowledge - not yet been identified.  
Deciphering the mechanism that leads to the creation of OnTEs is crucial to develop strategies 
to avoid them. And in line with this, identifying additional factors in the genome editing process 
that influence their occurrence, could prove very valuable to increase the efficiency of precise 
editing. Some of the factors that might affect OnTEs are 1) the cell cycle stage, 2) induction of 
SSBs by Cas9 nickase 3) DNA sequence characteristics or chromatin state of the surrounding 
sequence, 4) the type of Cas9 nuclease and 5) the design of the ssODN repair template for 
HDR-mediated editing. These factors will be discussed in more detail in the following 
paragraphs. 
 
4.4.1 Cell cycle stage 
The cells choice of a specific pathway to repair DSBs highly depends on the cell cycle stage 
(reviewed in Chapman et al., 2012; Hustedt & Durocher, 2017): the HDR pathway is restricted 
to the late S and G2 phase when the sister chromatid is available as a repair template. In 
contrast, the NHEJ pathway is active throughout the cell cycle, but mostly in the G1 and S 
phase. With the intent to increase the efficiency of precise genome editing by HDR, 
researchers have therefore restricted Cas9 activity to a specific cell cycle stage by 
posttranslational regulation (Gutschner et al., 2016). It is conceivable that also the mechanisms 
leading to OnTE occurrence underlay cell cycle stage-dependent regulation and it would 
therefore be interesting to investigate if such an approach would affect OnTE prevalence. 
 
4.4.2 Single-strand breaks by Cas9 nickase 
Previous studies investigated occurrence of OnTEs after induction of DSBs either by using WT 
Cas9 (Adikusuma et al., 2018; Kosicki et al., 2018; Owens et al., 2019) or dual Cas9 nickase 
with paired sgRNAs (Owens et al., 2019) to generate staggered DSBs. Newly developed 
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CRISPR-based genome editing tools like base editors and prime editors, however, use Cas9 
nickase that induces only SSBs into the genomic DNA (Anzalone et al., 2019; Komor et al., 
2016) and so far it is unclear if OnTEs also occur in these cases. Since cells usually choose 
less invasive pathways for repair of SSBs that involve only the replacement of a few 
nucleotides of the broken strand (reviewed in Caldecott, 2008), it seems less likely that repair 
mechanisms leading to large deletions or rearrangements are also active at these sites. 
However, it has been reported that MMEJ, the predominant pathway producing large deletions, 
also contributes to SSB repair, albeit with lower efficiency (Wang et al., 2019). This might be 
due to the fact that SSBs can also turn into DSBs, which can then lead to OnTEs. It therefore 
remains to be investigated to what extent this occurs after genome editing with Cas9 nickase 
versions.  
 
4.4.3 Surrounding DNA sequence and chromatin structure 
Several previous studies have shown that local DNA sequence (Allen et al., 2019; Shen et al., 
2018) as well as chromatin context (Schep et al., 2020; reviewed in Scully et al., 2019) 
surrounding the target locus greatly influence the choice of repair pathways after induction of 
DSBs by Cas9. However, experimental design often limited these studies to the investigation 
of smaller genomic changes well below 100 bp and could therefore not specifically determine 
the occurrence of large OnTEs. Nevertheless, it has been identified that DSB repair by the 
MMEJ pathway seems to be enhanced in heterochromatic regions (Schep et al., 2020), which 
could also suggest an increase of OnTEs caused by large deletions at these loci. Furthermore, 
large microhomologies around the cut site lead to an increase in large deletions, but in general 
there are strong differences between repair pathway choices at different loci with yet unknown 
underlying principles (Kosicki et al., 2020). 
In the presented study, we have analyzed three different loci, which is not sufficient to extract 
more features influencing the prevalence of other OnTEs like large insertions or LOH. It would 
therefore be interesting to investigate this further by testing more loci. This could help to design 
algorithms that predict OnTE occurrence to potentially guide the choice of sgRNAs for editing. 
 
4.4.4 Cas9 nuclease variants 
To overcome the problem of OffTE after genome editing, Cas9 nuclease variants with higher 
fidelity have been developed. For example, high-fidelity (HiFi) Cas9 carrying a single point 
mutation has been identified to retain on-target activity, while significantly reducing off-target 
activity (Vakulskas et al., 2018). The authors speculate that the mutation leads to impaired 
conformational change of the Cas9 nuclease from an inactive to an active state when 
mismatches between sgRNA and the target locus are present. It would therefore be interesting 
to investigate if this or other Cas9 variants, as identified by unbiased screens or rational protein 
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engineering, could also affect OnTE occurrence by slight changes in the molecular mechanism 
of initial Cas9 cleavage. Furthermore, not only the exact type of the nuclease used, but also 
different Cas9 delivery methods might influence OnTE prevalence, e.g., due to varying levels 
of cutting activity at the target site, which has been shown previously to affect DSB repair 
outcomes (Kosicki et al., 2020). We and others that investigated OnTE occurrence after 
CRIPSR editing, have used different Cas9 delivery methods, such as mRNA (Adikusuma et 
al., 2018; Shin et al., 2017), plasmids (Kosicki et al., 2018; Owens et al., 2019, our study) or 
RNPs (Kosicki et al., 2018, our study), but differences between those have never been 
investigated systematically. 
 
4.4.5 HDR repair template design  
Previous studies have shown an influence of ssODN orientation, asymmetry and length on the 
efficiency of genome editing by HDR (Richardson et al., 2016). It is therefore conceivable that 
these factors also have an effect on repair pathways that lead to OnTE occurrence. If such a 
correlation is identified at some point, modifying the ssODN design is relatively simple, which 
is a great advantage of this approach.  
 
Taken together, deciphering factors that influence OnTE occurrence and its underlying 
molecular mechanism could help preventing OnTEs from being generated in the first place.  
 
4.5 Preventing occurrence of OnTEs after CRISPR-editing 
Implementing above-mentioned strategies with potential influence on OnTE prevalence, could 
eventually lead to complete avoidance or at least a reduction of adverse events at the target 
locus. In this study, we identified OnTEs in up to 40% of CRISPR-edited clones, which we all 
had to exclude for subsequent experiments. Reducing the amount of faulty single-cell clones 
would have saved a lot of cost for media and consumables as well as time for clone picking 
and analysis. In addition, inhibiting OnTE occurrence would not only generally lower efforts for 
maintenance but could also automatically increase the rate of precision editing, which is still a 





With the simplicity of the CRISPR system, it is easy to forget that successful genome editing 
does not only involve creating the desired edit, but additionally requires thorough quality control 
analysis afterwards. Verifying accurate editing can sometimes take up more time than the 
editing process itself. This is due to the fact that CRISPR editing can be impaired by several 
inadvertent alterations in the genome (reviewed in Burgio & Teboul, 2020; Thomas et al., 
2019). Briefly, these include OffTE, random integration of editing components, or other 
chromosomal abnormalities like trisomies or translocations induced by the stressful editing 
process. Furthermore, it is important to exclude mix up of cell lines or animals during editing 
as well confirming clonality of cell lines (details for quality control analysis experiments can 
also be found in our second study).  In this thesis, we covered another problem after CRISPR 
editing, which is the occurrence of deleterious OnTEs, which we hope will soon gain 
widespread awareness in the field. This should lead - first and foremost - to increased use of 
OnTE detection methods.  
Overall, we believe it will be beneficial for the genome editing field to develop general 
guidelines for quality control after CRISPR editing that are adapted to the type of genome edit 
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